Completed drafting packet · October 18, 2026
Trulicity
AI-assisted draft, not yet reviewed
Explore the expanded explanation and evidence prepared for this medicine. This review edition is separate from the current visual guide.
Open the current guide and visual story →
Choose your perspective
Each view has its own explanation. Some older-page packets contain targeted FAQ repairs only; those are identified below.
Patient
Trulicity acts on GLP-1 receptors in the pancreas. When blood sugar is high, this helps the body release insulin and send less of a signal that raises sugar. It is a weekly shot, not insulin. A 36-week study found average A1c drops of about 1.5 to 1.8 points across three studied doses. A1c is a long-term blood sugar test. Your own change may differ. In a heart study of adults with type 2 diabetes and heart disease or risk factors, about 12 in 100 on Trulicity had death from heart or blood vessel disease, a heart attack or a stroke, versus about 13 in 100 on placebo over 5.4 years. It is not a weight-loss approval.
Limits: The A1c range is from AWARD-11 and not a personal forecast. REWIND tested a three-part cardiovascular outcome in eligible adults, not all patients or a proven single heart mechanism.
Safety: The boxed warning reports thyroid C-cell tumors in rats; whether this occurs in people is unknown. The label says Trulicity must not be used with a personal or family history of medullary thyroid cancer, MEN2, or a prior serious allergy to dulaglutide or its ingredients. Urgent symptoms and any treatment decision need a clinician.
Sources: Current US label §§1, 4–5, 12.1, 14.3–14.6; REWIND.
Questions for this perspective
20 drafted questions in this packet. A perspective-specific question set.
Safety: The boxed warning concerns thyroid C-cell tumors in rats. Risk in people is unknown. The label says this drug must not be used with a personal or family history of medullary thyroid cancer, MEN2, or a past serious allergy to dulaglutide or its ingredients. These are three formal contraindications. Label §§4–5.
patient-01 — What is this medicine used for?
Established. The label says dulaglutide can help lower blood sugar in adults and children age 10 and older with type 2 diabetes. It is used with food and activity plans. For adults with diabetes, it may also lower the chance of major heart problems if they have heart disease or several heart risks. It is not approved for weight loss, though weight may change during treatment. Ask the prescriber why it may fit your care plan and what goals you will track.
Sources: Trulicity US Prescribing Information, DailyMed §1
patient-02 — Why might it be prescribed for me?
Established. A prescriber may suggest dulaglutide to help manage type 2 diabetes. For some adults with diabetes, it can also lower the chance of major heart problems. The label covers adults with heart disease or more than one heart risk. It does not mean everyone with diabetes needs this drug. The choice depends on your health, other drugs, side effects, and goals. Ask your prescriber what reason applies to you and how you will check if it helps.
Sources: Trulicity US Prescribing Information, DailyMed §1; ADA Standards of Care in Diabetes—2026, §9
patient-03 — What improvement should I expect?
Established. Dulaglutide can help lower blood sugar over time. In a large study, adults taking it also had fewer major heart problems than adults taking placebo, but the result describes groups and does not promise what will happen to one person. The care team can follow blood sugar and discuss heart risk, side effects, and treatment goals. Do not judge the full effect from one day or one glucose reading.
Sources: Trulicity US Prescribing Information, DailyMed §1,14.5; Gerstein et al., REWIND, PMID 31189511
patient-04 — How soon should it start working?
Established. The medicine reaches its highest blood level about one to three days after an injection when used over time. That timing does not tell exactly when you will feel a change. The label says blood levels reach a steady pattern after two to four weeks of weekly use. Blood sugar checks and follow-up visits help the care team see how it is working. Ask the prescriber what measures and timing fit your plan.
Sources: Trulicity US Prescribing Information, DailyMed §12.3
patient-05 — How will I know whether it is helping?
Established. Your care team can check blood sugar and a longer-term sugar test to see how treatment is going. One reading can change from day to day. The team may also talk about heart risk if that applies to you. Tell them about stomach problems, low sugar if you use insulin or some diabetes pills, or changes in sight. They can look at the full pattern and discuss whether the plan meets your goals. Do not change your dose on your own.
Sources: Trulicity US Prescribing Information, DailyMed §§1,5.3,5.7,14.1
patient-06 — How does it work, in simple terms?
Established. Dulaglutide acts like a body signal called GLP-1. It helps the pancreas release insulin when blood sugar is high. It also lowers a signal that can raise blood sugar and slows food leaving the stomach. These actions can help with type 2 diabetes. This drug is not insulin. Low blood sugar can still happen, most of all when it is used with insulin or some other diabetes drugs. Ask the care team what signs to watch for.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,12.1–12.2
patient-07 — How much is usually taken, and how often?
Established. The label describes one injection each week. Adults usually start at 0.75 mg; after at least four weeks, the prescriber may raise the dose if needed. The highest adult dose is 4.5 mg weekly. For children aged 10 years and older, the label starts at 0.75 mg and allows up to 1.5 mg after at least four weeks. These are label schedules, not a personal dose change; follow the prescription and ask the care team questions.
Sources: Trulicity US Prescribing Information, DailyMed §§2.1–2.2
patient-08 — Should I take it with food?
Established. The injection can be given at any time of day, with or without food. It is not a pill that needs an empty stomach or a certain amount of water. The label lists the stomach area, thigh, or upper arm as injection sites. A pharmacist or nurse can show how to use the single-dose pen and check that the correct strength was supplied.
Sources: Trulicity US Prescribing Information, DailyMed §2.4, Instructions for Use
patient-09 — What should I do if I miss a dose?
Established. The label looks at how much time remains before the next weekly dose. It says a missed dose may be taken as soon as possible only if at least 3 days, or 72 hours, remain until the next scheduled dose. If less time remains, the label says to skip that dose and return to the regular day. This is not a rule to take it within 3 days after missing it. If unsure, call the pharmacist or prescriber.
Sources: Trulicity US Prescribing Information, DailyMed §2.3, Medication Guide
patient-10 — What if I accidentally take too much?
Uncertain. The label gives no home treatment plan for an extra shot. Call Poison Help or your care team promptly. Give the product name, strength, amount, and time. Too much dulaglutide may cause stomach problems or low blood sugar. Get emergency help for collapse, a seizure, trouble breathing, or if the person cannot wake up. Ask the care team about the next dose. In the United States, Poison Help is 1-800-222-1222.
Sources: Trulicity US Prescribing Information, DailyMed §10, Medication Guide; MedlinePlus dulaglutide, overdose In case of emergency/overdose
patient-11 — How long might treatment continue?
Uncertain. The label does not say how long one person should use dulaglutide. A prescriber can review blood sugar goals, heart risk, side effects, and other health changes over time. Do not stop or change the weekly plan on your own. Ask the care team to talk through the reasons and other choices. If you have severe belly pain, trouble breathing, or face or throat swelling, get urgent help and tell the team what drug you use.
Sources: Trulicity US Prescribing Information, DailyMed §1, Medication Guide
patient-12 — Can I stop when I feel better?
Established. Feeling better does not mean diabetes or heart risks are gone. The label describes weekly use, but the right plan depends on your health and goals. Talk with the prescriber before stopping or changing the dose, most of all if you use insulin or other diabetes drugs. For severe belly pain, trouble breathing, or swelling of the face or throat, get urgent help and tell the care team what drugs you use.
Sources: Trulicity US Prescribing Information, DailyMed §1,5.2,5.4, Medication Guide
patient-13 — What side effects are common?
Established. Nausea, loose stools, and vomiting were common in studies. These problems were more likely at higher doses, but study rates cannot predict what will happen to one person. Tell the care team if stomach problems last, make it hard to drink, or affect daily life. Low blood sugar is more likely if you also use insulin or a sulfonylurea. Ask how to spot low sugar and what to do based on your full medicine list.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,5.5,6.1
patient-14 — Which symptoms need urgent help?
Established. Get urgent help for trouble breathing or swelling of the face, lips, tongue, or throat. Severe belly pain that does not stop may be pancreatitis and needs prompt care. Call the care team about ongoing vomiting or diarrhea, which can dry you out and harm the kidneys, or a new change in sight. The boxed thyroid warning comes from tumors in rats. It is not known if people have the same risk. Report a neck lump, trouble swallowing, or lasting hoarseness.
Sources: Trulicity US Prescribing Information, DailyMed §§2,4,5.1–5.7, Medication Guide
patient-15 — Can it interact with medicines or supplements?
Established. Dulaglutide can slow the stomach, which may change how fast some pills are taken up by the body. The label says to check levels of some drugs with a narrow safe range, such as warfarin. Insulin and sulfonylurea diabetes pills can raise the chance of low blood sugar when used with dulaglutide. Tell the pharmacist and prescriber about all drugs, vitamins, and supplements. Ask before making a change to any medicine.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,7.1,12.2
patient-16 — What about alcohol, driving, and exercise?
Uncertain. The label does not give a set rule about alcohol or driving for dulaglutide. Low blood sugar can affect safe driving or exercise, most of all if you also use insulin or a sulfonylurea. Alcohol may also affect blood sugar. Ask your care team how to spot and treat low sugar during exercise, driving, or alcohol use. The right advice depends on your full medicine list and health plan. Follow any separate advice for your other drugs.
Sources: Trulicity US Prescribing Information, DailyMed §5.3
patient-17 — What about pregnancy, breastfeeding, or fertility?
Established. Tell your prescriber if you are pregnant, may become pregnant, or are breastfeeding. The label says there is not enough human data to know the risks in pregnancy. Animal studies found effects on fetal growth. It is not known if the drug passes into human milk or what effect it could have on a baby or milk supply. These facts cannot predict what will happen to one person. A clinician can discuss the risks and benefits for your case.
Sources: Trulicity US Prescribing Information, DailyMed §8.1,8.2
patient-18 — Will I need tests or monitoring?
Established. The care team may check blood sugar and ask how you feel. Tell them if you have eye disease from diabetes, since the label says to watch people with a history of this problem. Kidney health may need a check if vomiting or diarrhea causes loss of body fluid. If you also use insulin or a sulfonylurea, ask how to watch for low sugar. Bring your medicine list and recent readings to visits.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,5.5,5.7
patient-19 — Is there a generic or a lower-cost option?
Uncertain. A pharmacist can check your insurance, current products, and lower-cost choices. The FDA lists Trulicity as a biologic drug. Online cash prices can change and may not count toward insurance costs. Ask your pharmacy and health plan what you would pay before you change treatment. A different drug may not be right for you, so talk with the prescriber before any switch. Check current program terms because rules can change.
Sources: FDA Purple Book, BLA 125469 product record ; LillyDirect Trulicity purchase terms
patient-20 — What if it is not helping?
Established. Tell the care team what you have noticed. Bring blood sugar readings, missed shot dates, side effects, and your list of medicines. The label gives dose steps with at least four weeks at the current dose before a rise. The prescriber decides if a change fits your needs. More drug is not always the right answer. Ask what else could affect your results and how the team will check the plan.
Sources: Trulicity US Prescribing Information, DailyMed §§2.1–2.2, Medication Guide
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
Patient — Trulicity contains a long-acting fusion protein
Trulicity contains dulaglutide, a large protein made to copy part of a natural gut signal. It is joined to an Fc protein part that helps it last longer. The weekly pen gives a shot under the skin; the medicine is not insulin. The drawing shows parts of the protein, but cannot show its exact shape in your body.
Sources: Current label §§2, 11–12.
Patient — The design helps the medicine persist
The modified protein stays in the body for days rather than minutes. The label gives an average terminal half-life of about five days, which helps explain the weekly prescription. This does not mean the shot works at the same strength every moment. A pharmacist can check the pen schedule and the label's rule if a dose was missed.
Sources: Current label §§2.3, 12.3.
Patient — GLP-1 receptor activation raises cAMP
After the shot, dulaglutide reaches GLP-1 receptors on cells in the pancreas. A signal then builds inside those cells so they can respond when blood sugar is high. The name for one signal is cAMP; there is no need to measure it at home. Blood-sugar and A1c tests show the effects that matter in care.
Sources: Current label §12.1.
Patient — Insulin and glucagon responses improve glucose control
When sugar is high, the pancreas can send out more insulin and less glucagon, a signal that tells the liver to release sugar. This can lower glucose, but Trulicity is not insulin. Other diabetes medicines can still cause low sugar when used with it. Ask the care team which signs and readings need action for your plan.
Sources: Current label §§5.3, 7.2, 12.1.
Patient — Stomach emptying slows, especially early on
Trulicity can slow how fast food leaves the stomach, especially after the first shot. That effect often becomes smaller with later doses. Nausea may occur, but severe or lasting belly pain and trouble keeping fluids down need medical attention. This picture of slower movement does not mean food stops moving or explain every stomach symptom.
Sources: Current label §§5.2, 5.5, 6.1, 12.2.
Patient — REWIND tested cardiovascular outcomes
In REWIND, about 12 in 100 adults on dulaglutide had death from heart or blood vessel disease, a heart attack or a stroke, versus about 13 in 100 on placebo over a median 5.4 years. All had type 2 diabetes and heart disease or several risk factors. The result supports the adult heart-risk label, but does not promise one person's outcome or make this a weight-loss drug.
Sources: Current label §§1, 14.5; REWIND.
Caregiver
Dulaglutide works on GLP-1 receptors in the pancreas. It helps the body release insulin when blood sugar is high. A weekly Trulicity pen is not insulin. Watch for nausea, poor appetite, low fluid intake and vomiting. Write down the shot day, pen strength and sugar readings if the care team asks. This matters more when the person also uses insulin or a pill that raises insulin. Call the care team for lasting belly pain, trouble drinking, a new vision problem or signs of low sugar. In one group, 21.1% of adults using 1.5 mg reported nausea; this is not a forecast for one person.
Limits: This is an observe–record–report guide, not a dosing plan. The label's missed-dose rule depends on at least 72 hours remaining before the next scheduled dose; confirm any missed injection with the prescriber or pharmacist. Pediatric glycemic and adult cardiovascular indications differ.
Safety: Rat thyroid C-cell tumors underlie the boxed warning; human relevance is unknown. Personal/family medullary thyroid cancer, MEN2 and prior serious product hypersensitivity are contraindications. The pen is single use and must not be shared.
Sources: Current US label §§1–5, 6.1, 12.1, 14.5.
Questions for this perspective
8 drafted questions in this packet. A perspective-specific question set.
caregiver-03 — What is the correct routine?
Established. The label describes one injection each week, on the same day, at any time of day, with or without food. It lists the stomach area, thigh, or upper arm as injection sites. Each pen gives one dose and is thrown away after use. A health professional should show the person how to use the pen first. Writing down the day, dose, and site can help the family and care team keep the weekly routine clear.
Sources: Trulicity US Prescribing Information, DailyMed §§2.4,3,Instructions for Use
caregiver-05 — What about a missed or duplicated dose?
Established. The label bases a missed-dose choice on the time left before the next planned dose. It says a missed dose may be taken as soon as possible only when at least 3 days, or 72 hours, remain until the next scheduled dose. With less time, the label says to skip it and resume on the regular day. This is not a rule to wait 3 days after a missed dose. If an extra dose was given, call the prescriber or Poison Help for advice.
Sources: Trulicity US Prescribing Information, DailyMed §2.3, Medication Guide
caregiver-07 — What if they vomit after taking it?
Uncertain. The label has no rule to repeat a shot after vomiting. Vomiting does not show that the dose was lost. Do not guess about another shot; call the care team or pharmacist. Note when vomiting began and whether the person can keep drinks down. Ongoing vomiting or diarrhea can lead to loss of body fluid and harm the kidneys. Get urgent help for severe belly pain that will not stop, trouble breathing, or swelling of the face or throat.
Sources: Trulicity US Prescribing Information, DailyMed §§5.2,5.4–5.6, Medication Guide
caregiver-12 — Could side effects look like confusion or falls?
Established. Stomach upset can make a person weak or short of fluids. Low blood sugar may also cause shaking, sweating, confusion, or a fall. This risk is higher if the person also uses insulin or a sulfonylurea. Write down what happened, when it began, and any sugar reading. Tell the care team about a fall, trouble drinking, or repeat low readings. Do not assume confusion is only from stomach upset.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,5.5–5.6,6.1
caregiver-13 — Which changes should I report promptly?
Established. Call the care team about repeat vomiting or diarrhea, trouble keeping drinks down, or a change in sight. Fluid loss can hurt the kidneys. The label says a care team should check kidney health when stomach illness may dry a person out. People with a history of eye disease from diabetes should also report sight changes. Write down when each change began and the medicines being used. The care team can decide whether a check or visit is needed.
Sources: Trulicity US Prescribing Information, DailyMed §§5.5,5.7, Medication Guide
caregiver-14 — Which symptoms require emergency help?
Established. Get emergency help for trouble breathing, fainting, or swelling of the face, lips, tongue, or throat. These can be signs of a serious allergy. Severe belly pain that will not stop may be pancreatitis and needs prompt care. The boxed warning says to report a neck lump, trouble swallowing, or hoarse voice that lasts. The warning comes from tumors seen in rats. It is not known if the same risk occurs in people.
Sources: Trulicity US Prescribing Information, DailyMed §§2,4,5.1–5.2,5.4, Medication Guide
caregiver-17 — What should we record for the next appointment?
Established. A short list can help the care team. Write down the shot day, pen strength, and place used. Note nausea, diarrhea, vomiting, belly pain, fluid intake, and changes in sight. If the person also uses insulin or a sulfonylurea, note low sugar readings or signs. List all other medicines. Warfarin may need blood tests to check how well blood clots; the label says to monitor its level. Bring the list or pen box to the visit.
Sources: Trulicity US Prescribing Information, DailyMed §§2.4,5.3,5.5,5.7,7.1,16
caregiver-18 — How should we store and dispose of it?
Established. The label says pens stay in the fridge at 36–46°F (2–8°C), in their box away from light. They must not freeze. A pen may stay out of the fridge for a total of 14 days at up to 86°F (30°C). Each pen holds one dose. The label says a frozen pen must be thrown away. Ask the pharmacist about safe disposal, replacement, or any time spent outside these storage limits.
Sources: Trulicity US Prescribing Information, DailyMed §§3,16.1–16.2
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
Caregiver — Trulicity contains a long-acting fusion protein
At the medicine check, identify the single-dose Trulicity pen and its strength. Dulaglutide joins a GLP-1-like signal to an Fc protein part, so it is not insulin or a reusable pen. Record the weekly day set by the care plan and any device problem. A caregiver should use the exact pen instructions with the care team.
Sources: Current label §§2, 11, 16–17.
Caregiver — The design helps the medicine persist
A roughly five-day half-life means an injection persists beyond the day it is given. Keep a written record of the prescribed weekly day and any missed pen, especially when several people help. The label's missed-dose rule depends on at least 72 hours before the next scheduled dose. Ask a pharmacist to apply it to the actual schedule.
Sources: Current label §§2.3, 12.3.
Caregiver — GLP-1 receptor activation raises cAMP
Dulaglutide reaches pancreatic GLP-1 receptors after the shot and starts a cell signal called cAMP. That signal helps the pancreas respond to high blood sugar; a caregiver cannot judge it by how the person feels. Record glucose values only as the care plan requests. Report a change in readings or symptoms without assuming the pen failed.
Sources: Current label §12.1.
Caregiver — Insulin and glucagon responses improve glucose control
The pancreas can release more insulin and less glucagon when glucose is high. If insulin or a pill that raises insulin is also prescribed, low sugar can still happen. Watch for sweating, shaking or confusion and follow the person's written low-sugar plan. Keep that plan available to other caregivers and seek help for severe symptoms.
Sources: Current label §§5.3, 7.2, 12.1.
Caregiver — Stomach emptying slows, especially early on
The label measures the largest stomach-emptying delay after the first injection; a person may not feel that change. Write down nausea, vomiting, food and fluid intake, and whether an oral medicine seems hard to keep down. Persistent vomiting can lead to dehydration. Report severe belly pain or an inability to drink rather than treating every symptom as an expected adjustment.
Sources: Current label §§5.2, 5.5, 6.1, 12.2.
Caregiver — REWIND tested cardiovascular outcomes
REWIND counted a cardiovascular death, nonfatal heart attack or nonfatal stroke in 594 of 4,949 people on dulaglutide and 663 of 4,952 on placebo over a median 5.4 years. The adult label includes established heart disease or multiple risk factors, not all people using the pen. A caregiver can support follow-up and medicine records without promising protection to one person.
Sources: Current label §§1, 14.5; REWIND.
Pharmacist
Dulaglutide activates pancreatic GLP-1 receptors, raising beta-cell cAMP and glucose-dependent insulin secretion; reduced glucagon and slower gastric emptying add to glycemic effects. The Fc-fusion protein has a half-life of about five days, so reconcile duplicate GLP-1 therapy and the exact weekly pen before counseling. The adult label describes 0.75, 1.5, 3 and 4.5 mg strengths with staged escalation, rather than interchangeable pens. Gastric delay can alter the absorption rate of some oral medicines; assess drugs with narrow monitoring needs. A missed dose is label-eligible only when at least 72 hours remain before the next scheduled dose.
Limits: This summarizes label rules rather than directing a patient to start, escalate, skip or switch. The pediatric maximum is 1.5 mg weekly; check the current prescription, oral-drug list, storage conditions and device instructions. The gastric-emptying effect is largest after the first dose and attenuates later.
Safety: Boxed rat C-cell-tumor warning with unknown human relevance; personal/family MTC, MEN2 and serious dulaglutide/excipient hypersensitivity are contraindications. Review pancreatitis, dehydration/acute kidney injury, severe GI events, retinopathy history, gallbladder disease, aspiration context and hypoglycemia with insulin/secretagogues.
Role evidence: For adults, label §2.1 describes 0.75 mg weekly first, permits 1.5 mg after four weeks and further 1.5 mg increases only after at least four weeks at the current dose, to a maximum of 4.5 mg. Pediatric §2.2 has a 1.5 mg weekly maximum. These are product-label distinctions for prescription reconciliation, not a patient-specific escalation plan.
Sources: Current US label §§2–7, 11–12.
Questions for this perspective
8 drafted questions in this packet. A perspective-specific question set.
pharmacist-01 — What is the indication and licensing scope?
Established. The US label indicates dulaglutide with diet and exercise to improve glucose control in adults and pediatric patients aged 10 years and older with type 2 diabetes. It also indicates reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. The cardiovascular indication does not extend to children. Trulicity is not labeled for weight management or a separate kidney-outcome indication. Check the exact product label before applying evidence from another GLP-1 medicine.
Sources: Trulicity US Prescribing Information, DailyMed §1
pharmacist-02 — Is the dose appropriate for this patient?
Established. The adult label starts at 0.75 mg once weekly. After at least 4 weeks, it allows an increase to 1.5 mg; if more glycemic control is needed, further increases are in 1.5-mg steps after at least 4 weeks at the current dose, to a maximum of 4.5 mg weekly. Pediatric labeling starts at 0.75 mg and permits a maximum of 1.5 mg after at least 4 weeks if needed. These are label schedules, not an individualized order; verify the indication and prescription.
Sources: Trulicity US Prescribing Information, DailyMed §§2.1–2.2
pharmacist-03 — Which formulation, route, and release type apply?
Established. Trulicity is a clear, colorless solution in a single-dose subcutaneous pen, supplied as 0.75, 1.5, 3, or 4.5 mg per 0.5 mL. It is not an oral product or a multidose pen. The label names abdomen, thigh, and upper arm as injection sites and permits administration at any time of day with or without food. The Instructions for Use require user training. Confirm the exact pen strength and presentation when reconciling a prescription or device change.
Sources: Trulicity US Prescribing Information, DailyMed §§2.4,3,Instructions for Use
pharmacist-05 — What contraindications and allergy concerns matter?
Established. The formal contraindications are a personal or family history of medullary thyroid carcinoma, MEN2, or a prior serious hypersensitivity reaction to dulaglutide or any product component. The boxed warning reflects dose- and duration-related thyroid C-cell tumors in rats; whether this occurs in humans is unknown. Severe gastroparesis is a separate “not recommended” population, not a §4 contraindication. For a prior serious reaction to another GLP-1 receptor agonist, the label says predisposition with dulaglutide is unknown and advises caution.
Sources: Trulicity US Prescribing Information, DailyMed §§2,4,5.1,5.4,5.6
pharmacist-06 — Which drug interactions are important?
Established. Dulaglutide delays gastric emptying; the effect is largest after the first dose and diminishes with later doses. This can slow absorption of oral medicines. At 1.5 mg, tested oral medicines were not affected to a clinically relevant degree, but experience is limited at 3 and 4.5 mg. The label specifically says to monitor levels of narrow-therapeutic-index oral drugs such as warfarin. Insulin or sulfonylureas can raise hypoglycemia risk, so review the full regimen with the prescriber.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,7.1,12.2–12.3
pharmacist-08 — Where is therapeutic duplication a concern?
Established. Dulaglutide is a GLP-1 receptor agonist. During medication reconciliation, check for another GLP-1 receptor agonist or another dulaglutide product, including a recently changed prescription, to identify unintended duplicate therapy. The Trulicity label does not establish added benefit from combining it with another GLP-1 receptor agonist. Confirm prescriber intent rather than treating products in the same class as interchangeable. Also review insulin and sulfonylureas because their combination with dulaglutide can increase hypoglycemia risk.
Sources: Trulicity US Prescribing Information, DailyMed §§1,5.3,12.1
pharmacist-11 — What are the missed-dose instructions?
Established. The label’s missed-dose rule is measured from the next scheduled weekly dose. It says the missed injection may be given as soon as possible if at least 3 days (72 hours) remain until that next dose. If fewer than 3 days remain, the label says to skip the missed dose and return to the regular weekly schedule. The Medication Guide also warns against two doses within 3 days of each other. For a double dose or uncertain timing, refer to the prescriber or Poison Help.
Sources: Trulicity US Prescribing Information, DailyMed §2.3, Medication Guide
pharmacist-17 — What preparation, storage, and stability rules apply?
Established. The product is supplied as a single-dose pen; the Instructions for Use describe inspection, site selection, activation, and disposal. A health professional should train the patient or caregiver before first use. The label says to refrigerate at 36–46°F (2–8°C), protect from light, and avoid freezing. A pen may be kept at room temperature up to 86°F (30°C) for a total of 14 days. It recommends keeping pens in the original carton until administration. Verify excursions with the product-specific instructions.
Sources: Trulicity US Prescribing Information, DailyMed §§2.4,16.1–16.2,Instructions for Use
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
Pharmacist — Trulicity contains a long-acting fusion protein
Verify the actual single-dose pen before counseling: dulaglutide is a GLP-1 analogue linked to modified IgG4 Fc, not an insulin pen or an interchangeable milligram-strength device. The label describes staged strengths, with at least four weeks between escalation steps. Reconcile duplicate GLP-1 therapy and help the patient demonstrate the device instructions tied to the dispensed product.
Sources: Current label §§2, 11, 16–17.
Pharmacist — The design helps the medicine persist
Protein engineering supports roughly five days of terminal half-life, so a missed dose is a schedule question, not a quick replacement instruction. The label permits administration only when at least 72 hours remain before the next scheduled dose; otherwise it describes skipping. Check the precise written schedule and any duplicate injection before applying those label rules with the patient.
Sources: Current label §§2.3, 12.3.
Pharmacist — GLP-1 receptor activation raises cAMP
The GLP-1 analogue, not the Fc scaffold, activates beta-cell GLP-1R and its Gs–adenylyl cyclase–cAMP pathway. This explains glucose-dependent insulin support, yet it does not establish equal effect across GLP-1 products. For counseling, link the pathway to glucose monitoring and combination hypoglycemia risk while keeping molecule, formulation and label distinctions intact.
Sources: Current label §§5.3, 11–12.1; Glaesner.
Pharmacist — Insulin and glucagon responses improve glucose control
Increased glucose-dependent insulin and suppressed glucagon reduce fasting and after-meal glucose, but co-prescribed insulin or sulfonylureas can still drive hypoglycemia. Reconcile the full regimen and the person's written response plan. The label notes that the insulin or secretagogue prescriber may need to consider dose reduction; no automatic adjustment follows from the mechanism drawing.
Sources: Current label §§5.3, 7.2, 12.1.
Pharmacist — Stomach emptying slows, especially early on
Dulaglutide delays gastric emptying most after the first dose, with attenuation later. The label cautions that absorption of oral medicines may change, even though many studied drugs did not show clinically relevant effects. Identify oral drugs needing close efficacy or concentration monitoring, and separate this issue from nausea, vomiting and dehydration that may prevent a dose from staying down.
Sources: Current label §§5.2, 5.5, 7.1, 12.2.
Pharmacist — REWIND tested cardiovascular outcomes
The cardiovascular indication rests on REWIND, not simply GLP-1R signaling. Its primary composite occurred in 594/4,949 dulaglutide patients versus 663/4,952 placebo patients, HR 0.88 over median 5.4 years. Confirm that the prescription's patient population matches the adult label and distinguish pediatric glycemic approval from adult cardiovascular evidence during counseling.
Sources: Current label §§1, 14.5–14.6; REWIND.
Clinician
Dulaglutide stimulates islet GLP-1 receptors, increasing glucose-dependent insulin and reducing glucagon; this lowers HbA1c without identifying the mechanism of cardiovascular benefit. In REWIND, 9,901 adults with type 2 diabetes were followed a median 5.4 years; 31.5% had established cardiovascular disease. MACE occurred in 12.0% versus 13.4%, HR 0.88 (95% CI 0.79–0.99). AWARD-11 measured 36-week HbA1c changes of −1.5, −1.6 and −1.8 points at 1.5, 3 and 4.5 mg. Interpret those glycemic surrogates separately from REWIND, and review baseline retinopathy, GI tolerance and concomitant hypoglycemia risk.
Limits: REWIND's exact-count crude absolute difference of about 1.386 points gives a trial-specific reciprocal NNT ceiling of 73; it is not annualized. The retinopathy complication imbalance (1.9% versus 1.5%) does not establish a dulaglutide-specific causal pathway. Recheck exact guideline wording at implementation.
Safety: Boxed rodent C-cell-tumor warning with unknown human relevance; personal/family MTC, MEN2 and serious product hypersensitivity contraindicate use. Label warnings include pancreatitis, volume-related kidney injury, severe GI reactions, retinopathy complications, gallbladder disease, aspiration and combination hypoglycemia.
Role evidence: ADA 2026 §9 supports a GLP-1-based option with demonstrated cardiovascular benefit in the relevant type 2 diabetes risk setting independently of A1c, and prefers GLP-1-based therapy to insulin for initial/add-on glucose lowering when severe hyperglycemia or crisis is absent. In SURPASS-CVOT, tirzepatide versus dulaglutide 1.5 mg had HR 0.92 (95.3% CI 0.83–1.01): noninferiority met, superiority did not. These are professional context, not individual treatment directions.
Sources: Current US label §§1, 4–7, 12, 14.3–14.6; REWIND; ADA 2026 §9; SURPASS-CVOT.
Questions for this perspective
8 drafted questions in this packet. A perspective-specific question set.
clinician-01 — Where does this drug fit in treatment?
Established. The label covers glucose control from age 10 and cardiovascular-risk reduction in specified adults with type 2 diabetes. ADA 2026 §9 supports agents with demonstrated cardiovascular benefit in the relevant risk setting independently of A1c, while considering individual factors. Recommendation 9.21 prefers GLP-1-based therapy to insulin for initial or additional glucose lowering when severe hyperglycemia or crisis is absent. Product selection still depends on comorbidities, tolerability, concomitant therapy, access and patient preferences; another product’s indication is not interchangeable.
Sources: Trulicity US Prescribing Information, DailyMed §1; ADA Standards of Care in Diabetes—2026, §9 §9; ADA Standards of Care in Diabetes—2026, §10 §10
clinician-03 — How does it compare with alternatives?
Established. In SURPASS-CVOT, tirzepatide was compared with dulaglutide 1.5 mg in adults with type 2 diabetes and atherosclerotic cardiovascular disease. In the modified intention-to-treat population, MACE occurred in 801/6,586 versus 862/6,579; HR 0.92 (95.3% CI 0.83–1.01), meeting noninferiority (P=.003) but not superiority (P=.09). This is active-comparator evidence at 1.5 mg, not proof that the drugs are identical or that results apply to dulaglutide 3 or 4.5 mg.
Sources: Nicholls et al., SURPASS-CVOT, PMID 41406444 ; Trulicity US Prescribing Information, DailyMed §§2.1,14.5
clinician-04 — How large is the absolute clinical benefit?
Established. In REWIND, MACE occurred in 594/4,949 participants assigned dulaglutide and 663/4,952 assigned placebo over median 5.4 years; HR 0.88 (95% CI 0.79–0.99). From the exact counts, the crude absolute difference is about 1.386 percentage points and the reciprocal is about 72.14, so the strict upward-rounded NNT is 73 over observed follow-up. This descriptive calculation is not a time-to-event estimate. The label reports P=.026 for the primary endpoint.
Sources: Trulicity US Prescribing Information, DailyMed §14.5; Gerstein et al., REWIND, PMID 31189511
clinician-05 — Does it improve symptoms, outcomes, or a surrogate?
Established. AWARD-11 measured glycemic and weight outcomes at 36 weeks, not cardiovascular events. Mean HbA1c reductions were about 1.5, 1.6, and 1.8 percentage points with 1.5, 3, and 4.5 mg doses, respectively. REWIND separately measured cardiovascular outcomes over median 5.4 years and found fewer first MACE events with dulaglutide than placebo. Do not use an HbA1c change as a substitute for the REWIND outcome, or assume each patient will match the trial average.
Sources: Frias et al., AWARD-11, PMID 33397768 ; Trulicity US Prescribing Information, DailyMed §§14.3,14.5
clinician-06 — How applicable is the trial population to my patient?
Established. REWIND enrolled 9,901 adults aged 50 or older with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors. The label reports 31.5% with established disease and 62.8% without established disease but with multiple risk factors; these do not sum to 100%, so do not describe the remainder as confirmed primary prevention. Median follow-up was 5.4 years. Applicability depends on age, baseline risk, background care, and the patient’s fit with the trial criteria.
Sources: Trulicity US Prescribing Information, DailyMed §14.5; Gerstein et al., REWIND, PMID 31189511
clinician-07 — What starting dose and titration are labeled?
Established. For adults, the label starts 0.75 mg once weekly; after 4 weeks, the dose may rise to 1.5 mg. If more glycemic control is needed, it allows additional 1.5-mg increases after at least 4 weeks at the current dose, up to 4.5 mg weekly. For pediatric patients, the labeled start is 0.75 mg and maximum is 1.5 mg after at least 4 weeks if needed. These schedules describe the label; the prescription and clinical plan determine an individual dose.
Sources: Trulicity US Prescribing Information, DailyMed §§2.1–2.2
clinician-11 — Which outcomes and tests should be monitored?
Established. The label advises monitoring patients with a history of diabetic retinopathy for progression. In REWIND, retinopathy complications were 1.9% with dulaglutide and 1.5% with placebo overall; among those with baseline retinopathy, rates were 8.5% and 6.2%. Rapid improvement in glucose control has been associated with temporary worsening, so the difference does not prove direct retinal toxicity. Also review glucose control, GI tolerance, hydration and renal function when fluid loss occurs, and low-glucose risk with insulin or sulfonylureas.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,5.5,5.7,14.5
clinician-12 — What are the major contraindications?
Established. The label contraindicates dulaglutide in patients with a personal or family history of medullary thyroid carcinoma, MEN2, or serious hypersensitivity to dulaglutide or any product component. The boxed warning is based on thyroid C-cell tumors in rats; human relevance is unknown. Routine calcitonin testing or thyroid ultrasound has uncertain value for early detection according to the label. Severe gastroparesis is not a formal contraindication, but the label says Trulicity is not recommended in this population.
Sources: Trulicity US Prescribing Information, DailyMed §§2,4,5.1,5.4,5.6
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
Clinician — Trulicity contains a long-acting fusion protein
Dulaglutide is a roughly 63 kDa GLP-1 analogue–IgG4 Fc fusion, not an insulin formulation. Its weekly device and staged label escalation create exposure and tolerability questions before glycemic response can be interpreted. Distinguish the age-10-plus glucose indication from adult cardiovascular eligibility, and use the prescribed pen identity when comparing the patient's outcome with trial arms.
Sources: Current label §§1–2, 11, 14.
Clinician — The design helps the medicine persist
The Fc fusion helps prolong exposure; label PK gives median Tmax near 48 hours, about five days of terminal half-life and steady state after two to four weeks. A first-week glucose response is therefore not a full steady-state assessment. Consider titration phase, adherence and tolerability before labeling the receptor pathway ineffective, without converting these averages into a patient-specific concentration curve.
Sources: Current label §§2, 12.3.
Clinician — GLP-1 receptor activation raises cAMP
Pancreatic GLP-1R couples to Gs and raises beta-cell cAMP, supporting insulin secretion at elevated glucose. AWARD-11's 36-week HbA1c reductions of −1.5, −1.6 and −1.8 points across three doses are clinical surrogates downstream from that pathway. Neither cAMP nor A1c change proves the cardiovascular mediator. Review baseline A1c, concomitant therapies and the selected trial comparator before attributing an individual response.
Sources: Current label §§12.1, 14.3.
Clinician — Insulin and glucagon responses improve glucose control
Glucose-dependent beta-cell secretion and suppressed alpha-cell glucagon lower glucose through complementary islet effects. Combination insulin or sulfonylurea therapy changes hypoglycemia risk despite that dependence. Retinopathy complications were 1.9% versus 1.5% in REWIND; the label notes rapid glycemic improvement can be associated with temporary worsening, but does not show this caused the observed imbalance. Review baseline eye history.
Sources: Current label §§5.3, 5.7, 7.2, 12.1.
Clinician — Stomach emptying slows, especially early on
The early gastric-emptying delay can affect meal glucose and oral-drug timing, with attenuation after initial doses. Separate this pharmacodynamic effect from persistent vomiting, volume depletion or suspected pancreatitis. The label also discusses aspiration during anesthesia or deep sedation. Periprocedural planning needs current professional guidance and the individual clinical context; this animation establishes no universal interruption interval.
Sources: Current label §§5.2, 5.5, 5.9, 7.1, 12.2.
Clinician — REWIND tested cardiovascular outcomes
REWIND's 594/4,949 versus 663/4,952 primary events yielded HR 0.88, 95% CI 0.79–0.99, over median 5.4 years. Label population included 31.5% with confirmed established CVD and 62.8% without it but with multiple risk factors. The exact crude absolute difference is about 1.386 percentage points, reciprocal NNT ceiling 73. Keep that outcome separate from AWARD-11's A1c endpoint.
Sources: Current label §§1, 14.3–14.5; REWIND.
Nurse
Trulicity stimulates GLP-1 receptors in pancreatic beta cells, helping insulin rise when glucose is high. The weekly single-dose pen changes what to assess: confirm the prescribed device and use teach-back with its instructions rather than assuming the pen is reusable. Track glucose patterns, appetite, nausea, vomiting and hydration; delayed gastric emptying can affect how food and oral medicines move. Ask about a retinopathy history and report new vision changes. The label recorded retinopathy complications in 1.9% on Trulicity and 1.5% on placebo in REWIND, an observation that calls for monitoring, not a causal diagnosis.
Limits: A pen demonstration uses the exact device's Instructions for Use. The label's missed-dose rule requires at least 72 hours until the next scheduled dose; route individual timing questions to the prescriber or pharmacist.
Safety: Boxed rat C-cell-tumor warning with unknown human relevance; personal/family MTC, MEN2 and serious dulaglutide/excipient hypersensitivity are contraindications. Escalate severe persistent abdominal pain, dehydration, allergy or low-glucose symptoms, and note anesthesia/deep-sedation exposure.
Role evidence: The label describes one weekly injection on the same planned day, at any time with or without food. It lists abdomen, thigh and upper arm as sites and says to rotate sites; the pen is single-dose. The strength-specific Instructions for Use show no separate priming step. Demonstration must follow the exact dispensed pen, including disposal after use.
Sources: Current US label §§2–5, 12.1, 16–17 and Instructions for Use.
Questions for this perspective
8 drafted questions in this packet. A perspective-specific question set.
nurse-02 — What should I check before administration?
Established. Confirm the prescribed strength and the single-dose pen label, then check that the patient or caregiver has received device training. Ask about personal or family medullary thyroid cancer, MEN2, and serious allergy to dulaglutide or ingredients in the medicine because these are formal contraindications. Review insulin or sulfonylurea use, retinopathy history, and current severe stomach symptoms. The label lists injection into the abdomen, thigh, or upper arm, at any time of day, with or without food. Clarify unclear orders with the prescriber or pharmacist.
Sources: Trulicity US Prescribing Information, DailyMed §§2.4,3,4,5.1,5.3,5.6,Instructions for Use
nurse-05 — What is the correct administration technique?
Established. The label describes a once-weekly subcutaneous injection using a single-dose pen. The listed sites are the abdomen, thigh, or upper arm; the label permits any time of day and does not require a relation to food. The Instructions for Use show how to inspect the solution, place and unlock the pen, press the button, and wait for the second click before removing it. A trained clinician should demonstrate the device and observe teach-back before the first home dose.
Sources: Trulicity US Prescribing Information, DailyMed §2.4, Instructions for Use
nurse-06 — Does timing with food or medicines matter?
Established. Dulaglutide is injected once weekly at any time of day, with or without food. Unlike oral semaglutide, Trulicity has no fasting or water-volume rule. However, delayed stomach emptying can slow absorption of oral medicines, particularly after the first dose. The label recommends monitoring levels of narrow-therapeutic-index drugs such as warfarin. Review the medication list and follow any drug-specific monitoring plan; do not create a timing separation unless the product instructions or prescriber require it.
Sources: Trulicity US Prescribing Information, DailyMed §§2.4,7.1,12.2
nurse-09 — When should I reassess the patient?
Established. Assess glucose response and gastrointestinal tolerance over the planned treatment interval, while recognizing that dulaglutide reaches peak concentration about 24–72 hours after injection at steady state and reaches steady state after 2–4 weeks. The label does not set one universal bedside reassessment time. Reassess sooner for persistent vomiting or diarrhea, reduced fluid intake, severe abdominal pain, allergic symptoms, or vision changes. Use the patient’s care plan and escalation pathway, and document symptom onset, dose date, and concurrent glucose-lowering medicines.
Sources: Trulicity US Prescribing Information, DailyMed §§5.2,5.4–5.7,12.3
nurse-11 — What common adverse effects should I watch for?
Established. In adult placebo-controlled trials, nausea occurred in 12.4% with 0.75 mg and 21.1% with 1.5 mg, versus 5.3% with placebo; diarrhea was 8.9%, 12.6%, and 6.7%, respectively. Vomiting occurred in 6.0%, 12.7%, and 2.3%. These rates came from trial groups, not a forecast for one person. Watch for persistent symptoms that limit fluids, low glucose when insulin or sulfonylureas are also used, and changes in vision in patients with retinopathy history.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,5.5,5.7,6.1
nurse-12 — What requires immediate escalation?
Established. Breathing trouble, swelling of the face or throat, fainting, or a severe rash may signal anaphylaxis or angioedema and needs emergency escalation. Severe persistent abdominal pain may indicate pancreatitis. The boxed warning concerns thyroid C-cell tumors observed in rats; ask the prescriber about a neck mass, trouble swallowing, or persistent hoarseness, while explaining that human risk is unknown. Also escalate ongoing vomiting or diarrhea with dehydration signs and new vision changes according to the clinical pathway.
Sources: Trulicity US Prescribing Information, DailyMed §§2,4,5.1–5.7, Medication Guide
nurse-14 — What if a dose is missed, refused, or vomited?
Established. For a missed dose, the label uses the time remaining until the next scheduled dose: it may be given as soon as possible only if at least 3 days (72 hours) remain; with less time, the label says to skip and return to the regular day. This is not a “within 3 days after missing” rule. Vomiting after injection has no repeat-dose instruction in the label. For refusal, a duplicate dose, or uncertainty, document the facts and consult the prescriber or pharmacist.
Sources: Trulicity US Prescribing Information, DailyMed §2.3, Medication Guide
nurse-18 — What should teach-back check?
Established. Ask the patient to explain the weekly schedule, show the correct single-dose pen strength, name the listed injection sites, and describe how the pen is discarded after one use. Ask what they would report: severe belly pain, breathing or face swelling, ongoing vomiting or diarrhea, low-glucose symptoms with insulin or sulfonylureas, and vision changes. Confirm the patient can name their MTC/MEN2 contraindication history and knows the thyroid warning is based on rats with unknown human relevance. Use the current Instructions for Use during demonstration.
Sources: Trulicity US Prescribing Information, DailyMed §§2.4,3–5.7,Instructions for Use
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
Nurse — Trulicity contains a long-acting fusion protein
The dulaglutide fusion protein is supplied in a single-dose subcutaneous pen, so device identity is part of the safety assessment. Before demonstration, check the prescribed strength and the manufacturer's current Instructions for Use. Invite the patient to show how they would handle the pen, then correct observed gaps; do not treat a symbolic protein drawing as device training.
Sources: Current label §§2, 11, 16–17 and Instructions for Use.
Nurse — The design helps the medicine persist
The fusion's approximately five-day half-life helps explain why the care plan tracks a weekly injection day. Ask the patient to identify that day and whom they would contact about a missed pen. The label uses a 72-hour interval until the next scheduled dose; teach-back should reveal uncertainty, while individual timing belongs to the prescriber or pharmacist.
Sources: Current label §§2.3, 12.3.
Nurse — GLP-1 receptor activation raises cAMP
At pancreatic beta cells, GLP-1R signaling raises cAMP and supports insulin release when glucose is high. Nurses do not measure cAMP in routine care; follow the ordered glucose and A1c checks instead. If readings change unexpectedly, assess pen use, concomitant medicines, intake and illness before assuming the receptor mechanism has failed.
Sources: Current label §12.1.
Nurse — Insulin and glucagon responses improve glucose control
The pancreas can release more insulin and less glucagon at higher glucose. Review the medication list because insulin and sulfonylureas still raise low-sugar risk. Ask for a teach-back of the patient's approved low-glucose plan rather than inventing a target. In people with prior retinopathy, note visual complaints and the monitoring plan specified by the treating team.
Sources: Current label §§5.3, 5.7, 7.2, 12.1.
Nurse — Stomach emptying slows, especially early on
Because stomach emptying slows most after the first injection, ask about nausea, oral intake and fluid loss near treatment changes. Record persistent vomiting, dehydration signs and severe pain for prompt clinical review. A motility diagram should not normalize serious symptoms. Document Trulicity use when an anesthesia or deep-sedation team asks about current medicines.
Sources: Current label §§5.2, 5.5, 5.9, 6.1, 12.2.
Nurse — REWIND tested cardiovascular outcomes
In REWIND, major cardiovascular events affected 12.0% on dulaglutide and 13.4% on placebo over median 5.4 years. This trial supports the adult heart-risk indication, while glucose control also has a pediatric indication from age 10. During education, check which indication the clinician documented; a study average is not a promise for this patient.
Sources: Current label §§1, 14.5–14.6; REWIND.
Student
Dulaglutide binds class B GLP-1 receptors on pancreatic beta cells. Gs activates adenylyl cyclase, raising cAMP and amplifying glucose-dependent insulin secretion; reduced glucagon limits the liver's glucose-release signal. The molecule joins modified GLP-1 analogues to an IgG4 Fc scaffold, making a roughly 63 kDa protein with an approximately five-day terminal half-life. Those design features change exposure, not the identity of the receptor target. Gastric-emptying delay can slow oral-drug absorption, while insulin or sulfonylureas can still cause hypoglycemia. In a 36-week dose study, average HbA1c changes ranged from −1.5 to −1.8 points across studied strengths.
Limits: FcRn recycling and reduced renal filtration are plausible contributors to persistence, not a quantified decomposition of the human half-life. Exact residue substitutions need the full engineering paper. A GLP-1 receptor structure is not a dulaglutide-bound structure unless the deposited ligand is verified.
Sources: Current US label §§11–12, 14.3; Glaesner et al.; PDB 6X18.
Questions for this perspective
8 drafted questions in this packet. A perspective-specific question set.
student-01 — What drug class is this?
Established. Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist, or GLP-1 RA. It is a protein fusion medicine containing a modified GLP-1 analogue linked to a modified human IgG4 Fc fragment. The receptor is on pancreatic beta cells and couples to adenylyl cyclase. This distinguishes dulaglutide from insulin and from small-molecule glucose-lowering drugs. The long action supports once-weekly injection, while glucose-dependent signaling reduces but does not eliminate hypoglycemia risk with insulin or sulfonylureas.
Sources: Trulicity US Prescribing Information, DailyMed §§11,12.1,2.1; Glaesner et al., dulaglutide engineering, PMID 20503261
student-03 — What is the mechanism of action?
Established. Dulaglutide activates the GLP-1 receptor on pancreatic beta cells, a G-protein-coupled receptor linked to Gs and adenylyl cyclase. Increased cAMP supports glucose-dependent insulin release. It also reduces glucagon secretion and delays gastric emptying. These pathways lower glucose in type 2 diabetes; the receptor mechanism does not itself prove the separate cardiovascular benefit measured in REWIND. The label establishes the pharmacology and clinical indication, while the engineering study provides experimental characterization of the fusion agonist.
Sources: Trulicity US Prescribing Information, DailyMed §§1,12.1–12.2; Glaesner et al., dulaglutide engineering, PMID 20503261
student-05 — How is it absorbed, distributed, metabolized, and eliminated?
Established. At steady state after a shot under the skin, peak blood level occurs 24–72 hours later, with a median of 48 hours. Absolute bioavailability is 65% for 0.75 mg and 47% for 1.5 mg. Values at 3 and 4.5 mg were estimated from the 1.5-mg data and were not directly studied. Dulaglutide has an apparent central distribution volume of 3.09 L and peripheral volume of 5.98 L. Its half-life is about five days; the protein is thought to break down through normal protein breakdown.
Sources: Trulicity US Prescribing Information, DailyMed §12.3
student-06 — What determines onset and duration?
Established. A plasma peak is not the same as the time when a patient notices a glucose change. The label reports a median time to peak at steady state of 48 hours, with a 24–72-hour range, and steady state after 2–4 weeks of weekly dosing. The approximately 5-day elimination half-life supports prolonged exposure across a week. The label reports fasting and post-meal glucose reductions after one dose, but does not define one exact hour when a person will notice benefit. Glycemic response is assessed through clinical measurements over time, not inferred from peak concentration alone.
Sources: Trulicity US Prescribing Information, DailyMed §§12.3,14.1
student-10 — Which adverse effects follow from its pharmacology?
Established. GLP-1 receptor activation slows gastric emptying and can contribute to nausea and vomiting. Diarrhea and appetite changes are reported, but the label does not establish that delayed emptying alone causes each symptom. The same mechanism can slow absorption of oral medicines. Insulin release is glucose-dependent, but adding insulin or a sulfonylurea can still cause hypoglycemia because those drugs act through additional pathways. Retinopathy complications were observed in REWIND; the label links concern to rapid glucose improvement as a possible temporary worsening mechanism, not proven direct retinal toxicity from receptor binding.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,5.6–5.7,7.1,12.2,14.5
student-11 — What are the major contraindications?
Established. The label contraindicates dulaglutide with a personal or family history of medullary thyroid carcinoma, MEN2, or serious hypersensitivity to dulaglutide or any product component. Its boxed warning comes from dose- and time-related thyroid C-cell tumors in rats; whether the finding applies to humans is unknown. This is distinct from common GI effects or severe gastroparesis, for which the label says use is not recommended. The warning does not mean that every thyroid condition is a contraindication.
Sources: Trulicity US Prescribing Information, DailyMed §§2,4,5.1,5.4,5.6
student-12 — Which interactions matter most?
Established. Dulaglutide delays gastric emptying, so it may slow absorption of oral medicines, especially after the first dose; the effect becomes smaller with subsequent doses. At 1.5 mg, tested oral medicines were not affected to a clinically relevant degree, but experience with 3 and 4.5 mg is limited. The label specifically recommends monitoring levels of narrow-therapeutic-index drugs such as warfarin. Insulin and sulfonylureas can increase hypoglycemia risk. These are distinct mechanisms and call for medication-specific review.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,7.1,12.2–12.3
student-19 — What evidence established its clinical role?
Established. REWIND randomized 9,901 adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors to dulaglutide 1.5 mg or placebo plus usual care. Over median 5.4 years, MACE occurred in 594/4,949 versus 663/4,952; HR 0.88 (95% CI 0.79–0.99). The label indication covers adults with established disease or multiple risk factors. AWARD-11 separately tested glycemic dose response. These trials answer different questions: cardiovascular outcomes versus glucose and weight change.
Sources: Trulicity US Prescribing Information, DailyMed §§1,14.3,14.5; Gerstein et al., REWIND, PMID 31189511 ; Frias et al., AWARD-11, PMID 33397768
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
Student — Trulicity contains a long-acting fusion protein
Dulaglutide is a pair of modified GLP-1 analogues joined to modified IgG4 Fc chains, linked by disulfides. The roughly 63 kDa construct is a receptor agonist rather than insulin or an immune-targeting antibody. Name each molecular module before sketching its purpose: the GLP-1 domain addresses GLP-1R, while the Fc scaffold changes protein persistence.
Sources: Current label §§11–12.1; Glaesner.
Student — The design helps the medicine persist
The modified peptide resists rapid DPP-4 degradation, and its Fc fusion prolongs exposure relative to native GLP-1. In humans the label reports roughly five days of terminal half-life, not permanent receptor binding. FcRn recycling is a mechanistic hypothesis supported by Fc biology, but its fractional contribution to dulaglutide exposure is not quantified by this label.
Sources: Current label §§11–12.3; Glaesner.
Student — GLP-1 receptor activation raises cAMP
In beta cells, GLP-1R is a class B G-protein-coupled receptor. Gs stimulates adenylyl cyclase, producing cAMP and amplifying glucose-dependent insulin release. That pathway is an exam-level explanation, while A1c is a later clinical measurement. PDB 6X18 depicts GLP-1 bound to GLP-1R–Gs; it cannot prove dulaglutide's exact Fc orientation at the receptor.
Sources: Current label §12.1; PDB 6X18.
Student — Insulin and glucagon responses improve glucose control
Beta-cell insulin output rises with high glucose, while alpha-cell glucagon secretion falls, reducing liver glucose release. These endocrine branches help explain A1c lowering but do not guarantee freedom from hypoglycemia when insulin or a secretagogue is present. Distinguish receptor-dependent insulin support from injecting insulin, and identify concomitant therapy before interpreting a low reading.
Sources: Current label §§5.3, 7.2, 12.1.
Student — Stomach emptying slows, especially early on
The gastric-emptying effect is largest after the first dulaglutide dose and diminishes later. Slower nutrient arrival can shape postmeal glucose and oral-drug absorption, but it does not describe peptide elimination; the protein is broken down by general catabolism. Keep gastric pharmacodynamics, systemic pharmacokinetics and adverse GI symptoms as separate concepts in the diagram.
Sources: Current label §§7.1, 12.2–12.3.
Student — REWIND tested cardiovascular outcomes
REWIND measured cardiovascular death, nonfatal heart attack or nonfatal stroke, not receptor cAMP. The dulaglutide group had 594/4,949 events versus 663/4,952 on placebo, HR 0.88. Label eligibility included adults with established CVD or multiple risk factors. This randomized result supports a clinical indication but cannot assign a causal share to insulin, glucagon or gastric emptying.
Sources: Current label §§1, 14.5; REWIND.
Scientist
The target is islet GLP-1R: dulaglutide raises beta-cell cAMP and supports insulin secretion at elevated glucose. Glaesner and colleagues engineered a GLP-1 analogue–IgG4 Fc fusion to extend activity; the current label documents a roughly five-day human half-life, while the engineering experiments are a different evidence tier. REWIND supplies randomized endpoint evidence, HR 0.88, in a group mostly without established cardiovascular disease. Retinopathy complications were 1.9% versus 1.5%; the label links rapid glucose improvement with temporary worsening in general, but does not prove that mechanism caused this imbalance. Mediation of MACE remains open.
Limits: Binding/function, human PK and randomized outcome data answer different questions. PDB 6X18 depicts GLP-1 on GLP-1R–Gs, not a dulaglutide complex; it cannot establish fusion-protein contacts. The exact Fc mutation and substitution map requires full-source review.
Sources: Current US label §§5.7, 11–12, 14.5; Glaesner et al.; REWIND; PDB 6X18.
Questions for this perspective
8 drafted questions in this packet. A perspective-specific question set.
scientist-01 — What is the target and biological rationale?
Established. Dulaglutide activates the GLP-1 receptor, a class B G-protein-coupled receptor. In pancreatic beta cells, receptor signaling raises cAMP and supports glucose-dependent insulin secretion; it also reduces glucagon and slows gastric emptying. The label links this pharmacology to glucose control, while REWIND separately tested cardiovascular outcomes. The receptor mechanism alone cannot establish the cause of every clinical outcome. Human receptor localization and pathway biology should be distinguished from the trial evidence for benefit.
Sources: Trulicity US Prescribing Information, DailyMed §§12.1–12.2; Gerstein et al., REWIND, PMID 31189511
scientist-02 — What is known about the molecular design?
Established. Dulaglutide is a fusion of modified GLP-1 analogue sequences with a modified human IgG4 Fc fragment. The label describes changes intended to reduce DPP-4 breakdown and extend exposure. These design features do not prove there are no immune responses or define every Fc-receptor interaction. The cited engineering paper gives background on the construct, while clinical pharmacokinetics and immune response must be judged from product-specific studies.
Sources: Trulicity US Prescribing Information, DailyMed §11; Glaesner et al., dulaglutide engineering, PMID 20503261
scientist-03 — What mechanism explains the clinical effects?
Established. GLP-1 receptor activation couples through Gs and adenylyl cyclase, increasing cAMP and supporting glucose-dependent insulin release. The label also reports reduced glucagon and delayed gastric emptying. These actions explain glucose lowering and some gastrointestinal effects. They do not by themselves demonstrate why REWIND showed fewer cardiovascular events; that requires the randomized clinical outcome data. Treat the molecular pathway and the clinical endpoint as separate evidence layers.
Sources: Trulicity US Prescribing Information, DailyMed §§12.1–12.2; Gerstein et al., REWIND, PMID 31189511
scientist-04 — What does the pharmacokinetic profile show?
Established. At steady state, peak blood level occurs 24–72 hours after an injection, with a median of 48 hours. Steady state occurs after 2–4 weeks of weekly use, and the half-life is about 5 days. Apparent central and peripheral distribution volumes are 3.09 and 5.98 L. Absolute bioavailability at 3 and 4.5 mg was estimated from 1.5 mg data and was not directly studied; dulaglutide concentrations were dose-proportional. These data describe exposure, not exact onset of benefit.
Sources: Trulicity US Prescribing Information, DailyMed §12.3
scientist-05 — What evidence supports longer-acting exposure?
Established. The label reports an approximately 5-day elimination half-life and weekly administration. Glaesner et al. describe the fusion-protein engineering used to extend exposure compared with native GLP-1. The label says dulaglutide is presumed to be degraded through general protein catabolism; it does not provide a single specific organ clearance pathway. Do not infer a precise receptor recycling mechanism or human FcRn-binding behavior from the construct description alone.
Sources: Trulicity US Prescribing Information, DailyMed §§11,12.3; Glaesner et al., dulaglutide engineering, PMID 20503261
scientist-06 — What clinical outcomes were tested?
Established. REWIND tested dulaglutide 1.5 mg weekly against placebo for major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease or risk factors. The label reports 594/4,949 versus 663/4,952 events over median 5.4 years, HR 0.88 (95% CI 0.79–0.99). This supports the labeled adult cardiovascular-risk indication. It does not establish benefit for every cardiovascular endpoint, pediatric patients, or a different GLP-1 medicine.
Sources: Trulicity US Prescribing Information, DailyMed §§1,14.5; Gerstein et al., REWIND, PMID 31189511
scientist-07 — What evidence remains uncertain?
Uncertain. The label says absolute bioavailability at 3 and 4.5 mg was estimated from 1.5 mg data and was not directly studied. It also reports dose-proportional concentrations across doses. A follow-up study could directly measure absolute bioavailability at the higher doses, rather than treating all higher-dose pharmacokinetics as unknown. Separately, REWIND showed fewer major heart events, but the GLP-1 receptor pathway alone does not explain that trial result.
Sources: Trulicity US Prescribing Information, DailyMed §§12.1,12.3,14.5; Gerstein et al., REWIND, PMID 31189511
scientist-08 — What would a useful follow-up study measure?
Probable. A follow-up experiment could directly measure absolute bioavailability at 3 and 4.5 mg, which the label estimates as similar to 1.5 mg rather than reporting direct measurement. This is a specific exposure question: the label already reports dose-proportional concentrations across strengths. A separate randomized outcomes trial would be needed to determine whether higher doses alter cardiovascular events. Neither absolute bioavailability nor glycemic dose response establishes cardiovascular-outcome equivalence between doses.
Sources: Trulicity US Prescribing Information, DailyMed §§12.3,14.5
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
Scientist — Trulicity contains a long-acting fusion protein
Glaesner's engineering program joined a modified GLP-1 analogue to an IgG4 Fc scaffold; the marketed label describes two disulfide-linked chains near 63 kDa. Receptor and cell-function assays, protein production and human outcomes occupy separate evidence tiers. The Fc is designed for exposure, not antibody-mediated cell killing. A structural drawing should identify which features are label-verified and which need full primary figures.
Sources: Current label §11; Glaesner.
Scientist — The design helps the medicine persist
Human label PK reports a roughly five-day terminal half-life and two to four weeks to steady state. These observations test systemic persistence after injection, whereas the engineering paper's preclinical experiments tested design hypotheses. Quantifying FcRn recycling, reduced renal filtration or protease resistance as separate human contributors would need targeted measurements; do not assign their shares from half-life alone.
Sources: Current label §§11–12.3; Glaesner.
Scientist — GLP-1 receptor activation raises cAMP
GLP-1R agonism can be tested in receptor-linked cAMP assays and then in glucose-conditioned islet secretion. PDB 6X18 is a GLP-1–GLP-1R–Gs structure, not a dulaglutide-fusion structure. Use it to illustrate the class-level receptor state while avoiding claims about dulaglutide's Fc orientation, binding stoichiometry or residue contacts without a directly relevant structure.
Sources: Current label §12.1; PDB 6X18; Glaesner.
Scientist — Insulin and glucagon responses improve glucose control
The islet model predicts glucose-dependent beta-cell insulin and reduced alpha-cell glucagon. Human HbA1c data support downstream glycemic effect but do not apportion it between these branches. REWIND's retinopathy complications were 1.9% versus 1.5%; the label notes an association with rapid glycemic improvement generally, not a proven dulaglutide-mediated cause of this trial imbalance.
Sources: Current label §§5.7, 12.1, 14.3, 14.5.
Scientist — Stomach emptying slows, especially early on
Gastric emptying is a pharmacodynamic branch whose delay is largest after the initial dose and attenuates. A transit schematic cannot resolve motility measurements, nausea mechanisms or the extent of oral-drug interaction in each person. Distinguish these observations from the fusion protein's plasma kinetics. Testing a proposed mechanism of cardiovascular protection would require more than this stomach endpoint.
Sources: Current label §§7.1, 12.2–12.3.
Scientist — REWIND tested cardiovascular outcomes
In 9,901 randomized adults, REWIND observed 594/4,949 versus 663/4,952 primary events, HR 0.88 with 95% CI 0.79–0.99. The population included many without documented established CVD but with multiple risk factors. This is randomized endpoint evidence, not mediation analysis. The open problem is which tissue-level pathways, if any, account for the clinical risk difference.
Sources: Current label §14.5; REWIND.
Chemist
Dulaglutide is a roughly 63 kDa protein assembled from two identical, disulfide-linked chains, each joining a modified GLP-1 analogue to a modified human IgG4 Fc region. The GLP-1 parts activate pancreatic GLP-1R; the Fc scaffold supports an approximately five-day elimination half-life without making this an immune-targeting antibody. The label describes Fc modifications in regions related to high-affinity Fc-receptor binding and half-antibody formation. These features matter for architecture and persistence, while glucose-dependent insulin release is the functional readout. Show peptide, linkers, Fc and disulfides separately; PDB 6X18 illustrates GLP-1 receptor geometry, not dulaglutide's bound pose.
Limits: Do not assign exact amino-acid substitutions, glycosylation sites or atom-by-atom Fc contacts without checked primary figures. The cartoon need not imply the intact fusion contacts GLP-1R in the same pose as isolated GLP-1.
Sources: Current US label §§11–12; Glaesner et al.; PDB 6X18.
Questions for this perspective
8 drafted questions in this packet. A perspective-specific question set.
chemist-01 — What is the active molecular form?
Established. The labeled active ingredient is dulaglutide, a recombinant fusion protein made from modified GLP-1 analogue sequences linked to a modified human IgG4 Fc fragment. It is not a small-molecule salt. The label describes the active ingredient and molecular structure at a product level; formulation ingredients are listed separately. Avoid inferring additional chemical properties or a specific receptor-binding geometry that the prescribing information does not state.
Sources: Trulicity US Prescribing Information, DailyMed §§3,11
chemist-02 — How does the molecular design affect stability?
Established. The label describes amino-acid substitutions that reduce susceptibility to DPP-4 degradation and a fusion to modified IgG4 Fc that extends exposure. These are protein-engineering features, not a claim that the molecule cannot degrade or that it is stable under all storage conditions. The commercial pen must still be refrigerated as directed, protected from light, and never frozen. Keep molecular stability and in-use product storage as separate questions.
Sources: Trulicity US Prescribing Information, DailyMed §§11,16.1–16.2; Glaesner et al., dulaglutide engineering, PMID 20503261
chemist-03 — What is the formulation and concentration?
Established. Each Trulicity pen contains a clear, colorless solution for subcutaneous use, with 0.75, 1.5, 3, or 4.5 mg in 0.5 mL. The pen is a single-dose device, not a multidose vial. The label’s ingredient list includes sodium citrate, citric acid, mannitol, polysorbate 80, and water for injection. Confirm the strength on the actual carton when reconciling product or investigating a device concern.
Sources: Trulicity US Prescribing Information, DailyMed §3
chemist-04 — What is known about the protein structure?
Established. The label identifies dulaglutide as a fusion protein containing two modified GLP-1 analogue sequences linked to a modified human IgG4 Fc fragment. RCSB entry 6X18 is a structure of GLP-1 bound to GLP-1R with Gs, not a dulaglutide structure. It can illustrate receptor signaling context but cannot be presented as a direct structure of the marketed drug. The label and engineering paper are the appropriate sources for dulaglutide’s composition.
Sources: Trulicity US Prescribing Information, DailyMed §11; Glaesner et al., dulaglutide engineering, PMID 20503261 ; RCSB PDB 6X18, GLP-1-bound GLP-1R–Gs complex
chemist-05 — What degradation or elimination pathway is established?
Established. The label states that dulaglutide is presumed to be degraded into amino acid components through general protein catabolism. It does not identify one dominant enzyme, organ, or quantitative clearance fraction. The approximately 5-day half-life is a pharmacokinetic observation, not proof of a particular degradation pathway. Avoid assigning small-molecule hepatic metabolism or renal excretion mechanisms to this protein without direct evidence.
Sources: Trulicity US Prescribing Information, DailyMed §12.3
chemist-06 — How should the product be stored?
Established. The label says to store pens refrigerated at 36–46°F (2–8°C), protect them from light, and avoid freezing. A pen may be kept at room temperature up to 86°F (30°C) for a total of 14 days. Keep it in the original carton until use. If it has frozen, the label says to discard it; ask the pharmacist how to replace it. Do not judge suitability by appearance alone.
Sources: Trulicity US Prescribing Information, DailyMed §16.1–16.2
chemist-07 — What excipients are present?
Established. The solution contains sodium citrate, citric acid, mannitol, polysorbate 80, and water for injection. The active ingredient is the dulaglutide fusion protein. People with a prior serious hypersensitivity reaction to dulaglutide or any product component have a labeled contraindication. For a suspected excipient allergy, compare the full ingredient list with the exact presentation and consult a pharmacist or prescriber rather than assuming all injectable products share the same excipients.
Sources: Trulicity US Prescribing Information, DailyMed §§4,11
chemist-08 — What analytical limits should be kept in mind?
Uncertain. The prescribing information describes composition, concentration, and clinical pharmacokinetics but does not provide a full independent analytical characterization of every commercial lot. The listed pen contains a specified mass in 0.5 mL; it does not establish assay variability beyond regulatory quality controls. Questions about aggregation, particle levels, or lot-specific stability require manufacturer or regulator quality records. Do not infer those properties from the clear appearance of a pen.
Sources: Trulicity US Prescribing Information, DailyMed §3,12.3,16
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
Chemist — Trulicity contains a long-acting fusion protein
Draw dulaglutide as two identical polypeptide chains connected by disulfides, each with a modified GLP-1 analogue and a modified human IgG4 Fc segment. The label reports about 63 kDa and Fc modifications in regions related to high-affinity Fc-receptor binding and half-antibody formation. Mark domains rather than unverified residue positions; this biologic is not a small-molecule ligand.
Sources: Current label §11; Glaesner.
Chemist — The design helps the medicine persist
Modified peptide sequence and an Fc scaffold address distinct liabilities: protease-sensitive GLP-1 and rapid clearance of a small peptide. The label's approximately five-day half-life is a property of the final injected fusion in humans, not proof that any one modification supplies all persistence. Depict proteolytic catabolism and potential recycling as separate hypotheses unless direct measurements support a quantified route.
Sources: Current label §§11–12.3; Glaesner.
Chemist — GLP-1 receptor activation raises cAMP
The GLP-1-like domains provide agonism at the class B GLP-1 receptor, initiating Gs and cAMP signaling. PDB 6X18 contains GLP-1 bound to GLP-1R–Gs; it is a reference for receptor geometry, not an observed dulaglutide complex. Exact fusion-specific orientation, glycan placement or hydrogen bonds require direct structural evidence not supplied by this generic model.
Sources: Current label §§11–12.1; PDB 6X18.
Chemist — Insulin and glucagon responses improve glucose control
Receptor activation is a molecular event; glucose-dependent insulin release and reduced glucagon are cellular outputs. Chemical modification maintains an active GLP-1-like sequence while changing exposure, but neither a domain cartoon nor molecular mass predicts the measured HbA1c effect. Link the outcome to the 36-week clinical dose comparison rather than claiming a residue-specific efficacy gain.
Sources: Current label §§11–12.1, 14.3; Glaesner.
Chemist — Stomach emptying slows, especially early on
Delayed gastric emptying reflects receptor pharmacology after systemic exposure; it is not a slow-release pen design. The effect attenuates after initial dosing, while the protein's long plasma half-life persists. Keep these time courses visually separate. Metabolism by general protein catabolism is also different from an Fc-mediated effect on the stomach or a depot dissolution model.
Sources: Current label §§7.1, 12.2–12.3.
Chemist — REWIND tested cardiovascular outcomes
REWIND's 594/4,949 versus 663/4,952 event counts establish a clinical contrast beyond GLP-1R binding diagrams. The Fc fusion determines product identity and exposure, but no structure in this packet assigns the heart benefit to a specific domain or atomic contact. FDA labeling applies to the final biologic and the tested adult population, not a generic GLP-1 motif.
Sources: Current label §§1, 11, 14.5; REWIND.
Investor / Diligence Analyst
Trulicity's weekly GLP-1R agonism reaches pancreatic islets and has both glycemic and outcome evidence. REWIND enrolled 9,901 adults with type 2 diabetes; 31.5% had confirmed established cardiovascular disease, while a majority had multiple risk factors. MACE was 12.0% versus 13.4% over median 5.4 years, HR 0.88. That population supports the US label's established-disease-or-multiple-risk-factor wording; it does not prove a unique class benefit. Dulaglutide 1.5 mg served as the active comparator in SURPASS-CVOT against tirzepatide, so compare endpoint designs and populations before drawing competitive conclusions. Fc design supports weekly delivery but does not alone establish market durability.
Limits: Product revenue is not manufacturer net price, Medicare expenditure or worldwide volume. Company patent and biologics-protection dates are estimates, not legal clearance or a guaranteed biosimilar launch. Exact WAC, current inventory and undisclosed filings remain unverified. Active-comparator use does not prove superiority over all weekly agents.
Role evidence: Lilly's 2025 Form 10-K reports Trulicity product revenue of $4.276 billion versus $5.254 billion in 2024 and estimates 2027 US compound-patent and biologics-data-protection expiry. FDA's Purple Book lists BLA 125469. LillyDirect advertises a dated self-pay offer starting at $389 for four pens, subject to adult eligibility and separate terms; this is neither WAC nor typical insured cost. Compare with labeled weekly semaglutide and tirzepatide products without assuming identical indications. [VERIFY: recheck all dated commercial/IP terms and WAC at implementation.]
Sources: Current US label §§1, 11–12, 14.5; REWIND; SURPASS-CVOT; FDA Purple Book; Lilly 2025 Form 10-K; LillyDirect offer; offer terms.
Questions for this perspective
8 drafted questions in this packet. A perspective-specific question set.
analyst-01 — What is the relevant standard of care?
Established. Dulaglutide is one option within contemporary type 2 diabetes care, with a US label for glucose control and adult cardiovascular-risk reduction. ADA 2026 standards provide a broader treatment framework that considers comorbidities, goals, adverse effects, access, and patient preference. The label does not make dulaglutide the required choice for every patient or establish superiority over all alternatives. Apply guideline recommendations to the specific clinical context and current local practice.
Sources: Trulicity US Prescribing Information, DailyMed §1; ADA Standards of Care in Diabetes—2026, §9 ; ADA Standards of Care in Diabetes—2026, §10
analyst-02 — What meaningful differentiation is demonstrated?
Established. Dulaglutide has a weekly single-dose pen and an adult cardiovascular-risk indication supported by REWIND. Its label also covers glucose control in adults and children aged 10 years and older, while cardiovascular-risk reduction is adult-only. These are product attributes and evidence boundaries, not proof of superiority to every GLP-1 agent. Comparisons require matched populations, doses, endpoints, and follow-up; cross-trial event rates alone cannot establish a ranking.
Sources: Trulicity US Prescribing Information, DailyMed §1,2.4,14.5; Gerstein et al., REWIND, PMID 31189511
analyst-03 — How strong is the human efficacy evidence?
Established. REWIND randomized 9,901 adults with type 2 diabetes and cardiovascular disease or risk factors. MACE occurred in 594/4,949 dulaglutide participants and 663/4,952 placebo participants; HR 0.88 (95% CI 0.79–0.99), over median 5.4 years. The trial supports the label’s adult cardiovascular-risk indication. Absolute event differences are descriptive and depend on this study’s follow-up and population; they are not a guaranteed individual benefit.
Sources: Trulicity US Prescribing Information, DailyMed §14.5; Gerstein et al., REWIND, PMID 31189511
analyst-04 — Is the demonstrated benefit clinically meaningful?
Established. In REWIND, the crude event proportions were 12.0% with dulaglutide and 13.4% with placebo, a difference of about 1.4 percentage points over median 5.4 years. Exact counts give an absolute difference near 1.39 points and a strict upward-rounded reciprocal of 73; this is a descriptive NNT calculation, not the trial’s survival-adjusted estimate. The hazard ratio was 0.88. Patient-level benefit depends on baseline risk and time horizon.
Sources: Trulicity US Prescribing Information, DailyMed §14.5; Gerstein et al., REWIND, PMID 31189511
analyst-05 — How credible are the trial design and endpoints?
Established. REWIND was randomized, double-blind, and placebo-controlled, with adjudicated major cardiovascular events as its primary endpoint. It enrolled adults with type 2 diabetes, including people without established cardiovascular disease but with risk factors; 31.5% had established disease, 62.8% had multiple risk factors without established disease, and 5.7% were not classified in those groups. Its median follow-up was 5.4 years. These design features support interpretation within the enrolled population.
Sources: Trulicity US Prescribing Information, DailyMed §14.5; Gerstein et al., REWIND, PMID 31189511
analyst-06 — Which safety findings could limit adoption?
Established. Gastrointestinal effects are common and dose-related in trials; severe GI reactions and severe gastroparesis are relevant label limits. The label also includes warnings for pancreatitis, volume-depletion kidney injury, gallbladder disease, retinopathy complications, and hypersensitivity. Contraindications include personal or family MTC, MEN2, and serious product hypersensitivity. Safety review should account for diabetes co-therapy, prior retinopathy, hydration, and patient preferences rather than treating a single event rate as universal.
Sources: Trulicity US Prescribing Information, DailyMed §§4–6,14.5
analyst-07 — What is the regulatory and commercial position?
Established. FDA’s Purple Book lists Trulicity as BLA 125469, originally approved September 18, 2014, with current autoinjector presentations. Lilly’s 2025 Form 10-K estimates US compound and biologic data exclusivity expirations in 2027; this is a company estimate, not a guaranteed generic-entry date. The company reported Trulicity revenue of $4.276 billion in 2025 versus $5.254 billion in 2024. Recheck source filings and product status before external use. [VERIFY: dated source lock]
Sources: FDA Purple Book, BLA 125469 product record ; Eli Lilly 2025 Form 10-K, SEC EDGAR
analyst-08 — What access and price evidence is available?
Uncertain. LillyDirect lists a starting price of $389 per month for each strength, with terms stating four pens and eligibility conditions; this is a cash-pay program, not an insured net price. CMS reported 617,000 Medicare users and $4.898 billion in spending for the selected-drug period, which is not total market revenue. A current WAC figure and payer-level net price were not established in this review. Confirm terms, date, eligibility, and geography before using these figures. [VERIFY: dated source lock]
Sources: LillyDirect Trulicity pricing information ; LillyDirect Trulicity purchase terms ; CMS Medicare Drug Price Negotiation fact sheet, 2028
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
Investor / Diligence Analyst — Trulicity contains a long-acting fusion protein
The Fc-fused GLP-1R agonist is a biologic product, so value diligence must track manufacturing, device, distribution and biosimilar pathways as well as receptor validation. About 63 kDa and two linked chains describe the asset but do not establish manufacturing cost or exclusivity. Check the BLA and FDA Purple Book alongside Lilly filings before assigning competitive durability to the protein design.
Sources: Current label §§11–12; FDA Purple Book.
Investor / Diligence Analyst — The design helps the medicine persist
Five-day human half-life supports weekly dosing as a product attribute, but weekly GLP-1 competition also includes semaglutide and tirzepatide products with different labels. Test whether device burden, payer coverage and persistence explain real-world choice; pharmacokinetics alone cannot establish switching behavior. Separate receptor-class demand from this BLA's particular patent, device and formulation terms.
Sources: Current label §§2, 12.3; FDA Purple Book.
Investor / Diligence Analyst — GLP-1 receptor activation raises cAMP
Pancreatic GLP-1R signaling is a validated class mechanism, not a Trulicity-exclusive target claim. Diligence should connect this biology to measured HbA1c and REWIND outcomes, then ask where product-specific evidence differs. A receptor structure with GLP-1, such as 6X18, cannot defend a proprietary dulaglutide binding pose or its Fc-linked commercial advantage.
Sources: Current label §§12.1, 14; PDB 6X18.
Investor / Diligence Analyst — Insulin and glucagon responses improve glucose control
Glucose-dependent insulin and reduced glucagon establish a plausible clinical-value chain, but class mechanisms do not equal identical labels. AWARD-11 measured dose-specific HbA1c changes, while SURPASS-CVOT later used dulaglutide 1.5 mg as an active comparator against tirzepatide. Compare trial populations, endpoints and dose definitions before turning those studies into a market-share forecast.
Sources: Current label §§12.1, 14.3; SURPASS-CVOT.
Investor / Diligence Analyst — Stomach emptying slows, especially early on
Early gastric-emptying delay may affect tolerability and oral-drug management, which can influence adherence. The label gives nausea rates by studied dose, but a mechanistic cartoon cannot predict discontinuation or paid prescriptions. For commercial analysis, obtain refill, access and safety data separately; do not infer sales from a stomach animation or an adverse-event percentage alone.
Sources: Current label §§6.1, 7.1, 12.2.
Investor / Diligence Analyst — REWIND tested cardiovascular outcomes
REWIND counted 594/4,949 versus 663/4,952 MACE events, HR 0.88, over median 5.4 years. Label review reports 31.5% with established CVD and 62.8% without it but with multiple risk factors. That breadth is an indication-specific asset, not proof of unique GLP-1 class benefit. Compare Lilly's dated sales and patent filings with biosimilar status before pricing a durable advantage.
Sources: Current label §§1, 14.5; REWIND; Lilly annual reports; FDA Purple Book.
General
Trulicity acts on GLP-1 receptors in the pancreas, where it helps the body release insulin when blood sugar is high. It also reduces glucagon, a signal that makes the liver release sugar, and slows early stomach emptying. Its surprising feature is an Fc protein tail that helps the medicine last for a weekly shot, without making it an immune attack drug. In a 36-week study, average A1c fell by 1.5 to 1.8 points at three studied doses. A separate heart study measured fewer major events in eligible adults, but did not explain a single protective pathway.
Limits: The protein drawing is a schematic, not a dulaglutide-bound atomic structure. The adult cardiovascular and age-10-plus glycemic indications have different eligibility; Trulicity is not labeled for weight management.
Sources: Current US label §§1, 11–12, 14.3–14.6; REWIND.
Questions for this perspective
10 drafted questions in this packet. A perspective-specific question set.
other-01 — What is this drug?
Established. Dulaglutide is the generic name for Trulicity, a once-weekly injection used for type 2 diabetes. It belongs to a group of medicines that act like the body signal GLP-1. The US label includes blood sugar treatment for adults and children aged 10 years and older, plus a heart-risk benefit for certain adults. It is a prescription medicine and is not labeled as a weight-loss drug.
Sources: Trulicity US Prescribing Information, DailyMed §1,3
other-02 — What conditions does it treat?
Established. The US label covers blood sugar control for adults and children age 10 and older with type 2 diabetes, along with diet and exercise. It also covers lowering the chance of major heart problems in adults with type 2 diabetes who have heart disease or more than one heart risk. The heart-risk use is for adults only. Results for another GLP-1 drug do not always apply to dulaglutide, so check the drug and label.
Sources: Trulicity US Prescribing Information, DailyMed §1
other-03 — What are its generic and brand names?
Established. Dulaglutide is the generic name; Trulicity is its US brand name. It is a biologic medicine given by injection once a week. The FDA Purple Book lists it as BLA 125469, a biologics license application number. A pharmacist can check the product and pen strength on a prescription. Biologics follow naming rules that differ from many small-molecule pills. Check current FDA records because product status and market supply can change over time.
Sources: Trulicity US Prescribing Information, DailyMed §3; FDA Purple Book, BLA 125469 product record
other-04 — Why might someone need it?
Established. A clinician may prescribe dulaglutide to manage type 2 diabetes. For some adults with diabetes, the label also includes reducing the chance of major heart-related events. REWIND studied people with heart disease and people with several heart risk factors. That does not mean every person should use it. Treatment decisions depend on health history, other drugs, risks, goals, and personal preferences. A clinician can explain how this evidence fits an individual care plan.
Sources: Trulicity US Prescribing Information, DailyMed §1,14.5; Gerstein et al., REWIND, PMID 31189511
other-05 — How does it work in everyday language?
Established. Dulaglutide acts like a natural gut hormone signal called GLP-1. It helps the body release insulin when blood sugar is high, lowers a signal that can raise blood sugar, and slows stomach emptying. That can help manage type 2 diabetes, while also causing nausea or other stomach effects. It is different from insulin, and low blood sugar can still occur when combined with certain diabetes medicines.
Sources: Trulicity US Prescribing Information, DailyMed §§5.3,12.1–12.2
other-06 — Where in the body does it act?
Established. Dulaglutide acts on GLP-1 receptors, including ones on cells in the pancreas that help control insulin release. The label also says it lowers glucagon and slows stomach emptying. These actions help explain its role in type 2 diabetes care. The exact reason it lowered heart events in a trial is not fully explained by the receptor action alone. That heart benefit comes from clinical trial results, which are a different kind of evidence.
Sources: Trulicity US Prescribing Information, DailyMed §§12.1–12.2,14.5
other-07 — Does it treat a cause, a symptom, or future risk?
Established. Dulaglutide helps manage blood sugar in type 2 diabetes. For some adults with diabetes, it can also lower the chance of future major heart problems. It does not cure diabetes or replace all care. People may still need food and activity plans, blood sugar checks, or other drugs. A clinician can explain which goals matter for one person and whether the likely benefits fit their health history and choices.
Sources: Trulicity US Prescribing Information, DailyMed §1
other-08 — How quickly does it work?
Established. The medicine’s blood level peaks about one to three days after an injection at steady state, but that does not mean a person will feel a change at that time. The label reports that steady drug levels develop after two to four weeks of weekly use. Blood sugar response is checked with measurements over time. The timing can differ across people, so a clinician should set expectations for follow-up.
Sources: Trulicity US Prescribing Information, DailyMed §12.3
other-09 — Why do people respond differently?
Established. People differ in starting blood sugar, other illnesses, medicines, dose, and regular use of treatment. Side effects also vary from person to person. Trial averages cannot predict how much one person’s blood sugar will change. Clinicians review readings, health goals, side effects, and patient preferences over time. These observations help assess whether a plan is useful. They may not show the reason for each difference in response.
Sources: Trulicity US Prescribing Information, DailyMed §§6.1,14.1,14.3
other-10 — How was it discovered?
Established. Dulaglutide grew from research on the natural GLP-1 hormone signal. Scientists joined modified GLP-1 pieces to an antibody-derived Fc protein tail. The design helped the medicine last longer and supported weekly dosing. Glaesner and colleagues described this engineering work in a 2010 paper. Their tests measured receptor activity and effects in cells and animals. Later human trials tested glucose control and heart outcomes. The protein design alone could not predict those clinical results.
Sources: Glaesner et al., dulaglutide engineering, PMID 20503261 ; Trulicity US Prescribing Information, DailyMed §11
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
General — Trulicity contains a long-acting fusion protein
Trulicity is built from a gut-hormone-like piece joined to an Fc protein tail. The active part can signal to cells in the pancreas, while the tail helps the whole medicine last longer. It is a weekly injection, not an insulin shot or an antibody that attacks cells. The drawing is a map of parts, not a photograph of the protein.
Sources: Current label §§2, 11–12.
General — The design helps the medicine persist
Many natural gut signals disappear quickly, but dulaglutide's engineered protein remains in blood for days. The label gives a terminal half-life near five days and a weekly dosing schedule. Those are group measures, not a clock for exactly when one person's effect begins or ends. Persistence helps explain the schedule without making the medicine permanently bound to its receptor.
Sources: Current label §§2, 12.3.
General — GLP-1 receptor activation raises cAMP
In the pancreas, dulaglutide touches GLP-1 receptors that pass a signal into the cell. One messenger, cAMP, helps insulin-making cells respond when sugar is high. You cannot feel or measure cAMP with a home glucose meter. The meter and the A1c blood test show later changes, which differ among people and doses.
Sources: Current label §12.1.
General — Insulin and glucagon responses improve glucose control
The pancreas can make more insulin when sugar is high and send less glucagon, a message that raises sugar from the liver. Both changes help explain lower glucose. The shot is still not insulin, and taking it with insulin or certain diabetes pills can raise low-sugar risk. The medicine list matters when judging symptoms.
Sources: Current label §§5.3, 7.2, 12.1.
General — Stomach emptying slows, especially early on
Food can leave the stomach more slowly after Trulicity, especially following the first injection. The delay tends to lessen later; it does not mean the stomach is blocked. This branch can affect how quickly sugar from a meal appears in blood and how some swallowed medicines are absorbed. A separate medical review is needed for severe or lasting stomach symptoms.
Sources: Current label §§5.5, 7.1, 12.2.
General — REWIND tested cardiovascular outcomes
REWIND followed 9,901 adults with type 2 diabetes for a median 5.4 years. The combined heart-death, nonfatal-heart-attack or nonfatal-stroke outcome affected 12.0% on dulaglutide and 13.4% on placebo. The group included people with established heart or blood vessel disease and others with several risk factors. The trial supports a specific adult label, not a guarantee of protection or an approved weight-loss use.
Sources: Current label §§1, 14.5; REWIND.
Trials, pharmacokinetics and questions to ask
These blocks describe US Trulicity single-dose pens. Treatment selection and dose changes belong with the prescriber and pharmacist.
Key safety information: The boxed warning concerns thyroid C-cell tumors in rats; human relevance is unknown. Personal/family medullary thyroid carcinoma, MEN2 and prior serious allergy to dulaglutide or its ingredients are contraindications. Warnings cover pancreatitis, hypoglycemia with insulin or insulin secretagogues, serious allergy, dehydration-related kidney injury, severe gastrointestinal reactions, retinopathy complications, gallbladder disease and aspiration during anesthesia or deep sedation. Postmarketing reports also include intestinal obstruction and severe constipation, including fecal impaction; voluntary reports cannot establish incidence or causality. Trulicity is not recommended with severe gastroparesis. Pregnancy use requires weighing potential benefit against fetal risk; human milk/infant-effect data are absent, and the label calls for considering breastfeeding benefits and maternal need. This selective summary does not replace the Medication Guide. US label §§4–5, 8.
Pharmacokinetics and pharmacodynamics at a glance
| Parameter | Label finding | Interpretation |
|---|---|---|
| Subcutaneous bioavailability | Mean 65% at 0.75 mg; 47% at 1.5 mg after single doses | Dose-specific absolute fractions; no oral formulation. |
| Higher-dose bioavailability | 3 mg/4.5 mg estimated similar to 1.5 mg, not specifically studied | An estimate is not a measured dose-specific result. |
| Tmax at steady state | 24–72 hours; median 48 hours | Plasma peak timing, not a promise about symptom relief. |
| Steady state | 2–4 weeks with weekly administration | Accumulation takes several doses. |
| Accumulation ratio | Approximately 1.56 at steady state | Exposure accumulation is distinct from dose escalation. |
| Dose proportionality | Concentrations approximately proportional across 0.75–4.5 mg | Does not establish proportional clinical benefit. |
| Distribution | Apparent population mean central 3.09 L; peripheral 5.98 L | Model parameters, not directly measured organ concentrations. |
| Clearance | Apparent population mean 0.142 L/hour | Do not remove the apparent/population qualifiers. |
| Elimination half-life | Approximately 5 days | Supports weekly exposure; not an exact duration for every effect. |
| Metabolism | Presumed general protein catabolism into amino acids | No CYP-mediated small-molecule pathway is established here. |
| Administration site | No statistically significant exposure effect across abdomen, thigh and upper arm | Label injection-site rotation still applies. |
| Glucose effect | Fasting and post-meal reductions observed after one dose | A1c and cardiovascular outcomes require different observation periods. |
Source: label §§12.2–12.3. The label supplies no urinary/fecal mass-balance percentages or measured tissue concentration map; no values are invented.
Interactions and organ function: Gastric emptying slows most after the first dose and less after later doses; adequate escalation attenuates the dose-related delay. Tested oral drugs at 1.5 mg showed no clinically relevant absorption change, but experience at 3 mg/4.5 mg is limited. The label calls for monitoring narrow-therapeutic-index oral medicines, such as warfarin. Insulin/sulfonylurea combinations raise hypoglycemia risk. No renal dose adjustment is recommended, including ESRD, but ESRD caution and kidney monitoring during severe GI symptoms remain. Hepatic clinical experience is limited despite no clinically relevant PK change. Label §§7, 8.6–8.7, 12.3.
What the label says about the pen and schedule
| Topic | Label description | Why it matters |
|---|---|---|
| Adult escalation | Starts 0.75 mg weekly; after 4 weeks may increase to 1.5 mg for additional glucose control; subsequent 1.5 mg increments after at least 4 weeks at the current dose; maximum 4.5 mg weekly | Escalation reduces GI-reaction risk and is a prescribing decision. |
| Pediatric escalation | Age 10+ starts 0.75 mg weekly; maximum 1.5 mg after at least 4 weeks if more glucose control is needed | Adult 3 mg/4.5 mg steps are not pediatric dosing. |
| Missed dose | The label permits administration if at least 72 hours remain until the next scheduled dose; otherwise it says skip the missed dose and resume the scheduled day | The audit's “within three days” shorthand was ambiguous and is replaced. |
| Change of weekly day | At least 3 days must have passed since the previous dose | Separate from the time-until-next-dose rule. |
| Administration | Subcutaneous abdomen/thigh/upper arm; any time, with or without food; rotate sites | A trained person should demonstrate the exact pen. |
| Pen | Each 0.5 mL pen contains one fixed dose and is used once | No dose dialing, dose sharing or insulin mixing. |
| Insulin | Separate injections; same body region is allowed but not adjacent sites | These are different medicines. |
| Storage | Refrigerated 2–8°C; if needed, total 14 days at room temperature not exceeding 30°C; no freezing; protect from light in original carton | No reset of the 14-day allowance by re-refrigerating is supplied. |
Source: label §§2–3, 16 and product Instructions for Use. These are label descriptions, not a personal dosing or switching plan. A device animation must be checked against the actual strength-specific IFU before implementation.
REWIND — cardiovascular outcomes
Adults aged 50+ with T2D and cardiovascular disease or risk factors received dulaglutide 1.5 mg weekly or placebo in addition to standard care. Among 9,901 randomized participants, the label identifies 31.5% with confirmed cardiovascular disease and 62.8% without confirmed disease but with multiple risk factors; EMA identifies the remaining 5.7% as missing/unknown baseline disease status. Do not turn the arithmetic complement 68.5% into a fully documented primary-prevention subgroup. Median follow-up was 5.4 years. Label §14.5; EMA assessment.
| Outcome | Dulaglutide | Placebo | Effect |
|---|---|---|---|
| CV death, nonfatal heart attack or nonfatal stroke | 594/4,949 (12.0%) | 663/4,952 (13.4%) | HR 0.88; 95% CI 0.79–0.99; p = .026. |
| Nonfatal stroke | 135(2.7%) | 175(3.5%) | HR 0.76; 95% CI 0.61–0.95; descriptive component. |
| CV death | 317(6.4%) | 346(7.0%) | HR 0.91; 95% CI 0.78–1.06; descriptive component. |
| Nonfatal heart attack | 205(4.1%) | 212(4.3%) | HR 0.96; 95% CI 0.79–1.16; descriptive component. |
Absolute interpretation: Exact-count crude risks differ by 1.386105 percentage points (about 14 fewer per 1,000 over the observed follow-up); its reciprocal is 72.1446, or 72.14, rounded upward to 73. Rounded label risks (12.0% and 13.4%) yield 1.4 points and a reciprocal of 71.43, rounded upward to 72. These crude summaries do not account for censoring, and are not individualized or fixed-time survival NNTs. The audit's “about 71” uses rounding without this distinction. Component confidence intervals are unadjusted for multiplicity; the label says not to infer separate statistical significance. Overall benefit is not proof of benefit in every subgroup or proof of a particular molecular heart pathway. Gerstein 2019, PMID 31189511; label Table 14.
Plain-language trial summary: Over about five years, a heart attack, stroke or death from heart disease occurred in about 120 per 1,000 adults on the drug. About 134 per 1,000 on placebo had one of these events; both groups had usual care.
AWARD-11 — dose response on background metformin
The double-blind trial randomized 1,842 adults with T2D to weekly 1.5 mg, 3 mg or 4.5 mg; the primary time point was 36 weeks. Everyone began at 0.75 mg and advanced in study-defined steps. This compares dulaglutide doses, not placebo or competing molecules. Label §14.3, Table 6; Frias 2021, PMID 33397768.
| Label Table 6 measure | 1.5 mg (n=612) | 3 mg (n=616) | 4.5 mg (n=614) |
|---|---|---|---|
| Baseline A1c | 8.6% | 8.6% | 8.6% |
| Mean adjusted change at 36 weeks | −1.5 points | −1.6 points | −1.8 points |
| Adjusted difference versus 1.5 mg (95% CI) | Reference | −0.1 (−0.2, 0.0) | −0.2 (−0.4, −0.1) |
| A1c below 7% | 50% | 56% | 62% |
| Mean weight change | −3.0 kg | −3.8 kg | −4.6 kg |
These are the label's rounded ITT estimates with multiple imputation; missing A1c-target data count as nonresponse. The adjusted 4.5 mg contrast is −0.2 points as reported, not a recomputed −0.3 from rounded group means. Do not splice different paper estimands into this table. A1c is a surrogate; weight change in T2D does not grant an obesity indication. An A1c mean has no event-risk NNT.
Plain-language trial summary: At 36 weeks, about 50 in 100 adults on the 1.5 mg dose reached an A1c below 7%, versus 56 on 3 mg and 62 on 4.5 mg. All took metformin, and this blood sugar goal is not a test of heart risk.
AWARD-PEDS — youth with T2D
This 26-week placebo-controlled trial included 154 participants aged 10–17, with or without metformin and/or basal insulin, followed by an open-label extension. Label Table 15 reports baseline-to-week 26 A1c changes of +0.6 points with placebo, −0.6 with 0.75 mg and −0.9 with 1.5 mg; pooled drug-minus-placebo difference −1.4 points (95% CI −1.9 to −0.8). The pediatric maximum remains 1.5 mg, and the adult cardiovascular indication does not extend to children. Label §§2.2, 14.6; Arslanian 2022.
The label reports 52% of pooled dulaglutide recipients versus 14% on placebo reaching A1c <7%; the journal abstract reports 51% versus 14%. Keep each source's stated rounding/analysis rather than mixing them. The trial did not show a between-group BMI benefit. No child-specific cardiovascular or weight-management claim follows.
Plain-language trial summary: At 26 weeks, about 52 in 100 youths on the drug reached an A1c below 7%, versus 14 on placebo, the label says. The study found better blood sugar control but no benefit for body mass index.
SURPASS-CVOT — an active comparator, not a superiority win
In adults with T2D and established atherosclerotic cardiovascular disease, tirzepatide up to 15 mg weekly was compared with dulaglutide 1.5 mg weekly. Of 13,299 randomized participants, 134 were excluded for eligibility failures; the paper's modified-ITT analysis includes 6,586/6,579. MACE occurred in 801 (12.2%)/862 (13.1%), respectively; HR 0.92 with 95.3% CI 0.83–1.01, p = .003 for noninferiority and p = .09 for superiority. The noninferiority margin was 1.05. Do not substitute the Mounjaro label's all-randomized-and-treated counts or p-value into the paper population. Nicholls 2025, PMID 41406444.
A lower observed event proportion does not establish incremental superiority. No beneficial NNT is presented for this nonsuperior contrast. Dulaglutide's role as a proven active comparator supports its evidence base; it does not establish equal effects, nor compare tirzepatide with dulaglutide 4.5 mg.
Plain-language trial summary: In the trial, a heart attack, stroke or heart-related death occurred in about 122 per 1,000 on tirzepatide, versus 131 on dulaglutide. The study met its set test for being no worse, but did not prove that tirzepatide was better.
Side effects and eye safety in context
In the adult placebo-controlled pool, mean dulaglutide exposure was 23.8 weeks. Rates are percentages of people, not first-week risks. Label §§5.7, 6.1.
| Reaction | Placebo(n=568) | 0.75 mg(n=836) | 1.5 mg(n=834) |
|---|---|---|---|
| Nausea | 5.3% | 12.4% | 21.1% |
| Diarrhea | 6.7% | 8.9% | 12.6% |
| Vomiting | 2.3% | 6.0% | 12.7% |
| Abdominal pain | 4.9% | 6.5% | 9.4% |
| Reduced appetite | 1.6% | 4.9% | 8.6% |
| Stopped due to GI reactions | 0.2% | 1.3% | 3.5% |
Retinopathy complications in REWIND were 1.9% versus 1.5% overall, 8.5% versus 6.2% with a baseline retinopathy history, and 1% versus 1% without one. These were prospectively assessed secondary-composite events over median 5.4 years. Rapid glucose improvement is associated with temporary retinopathy worsening, but this does not prove it mediated the observed difference or exclude other explanations. The label calls for monitoring people with a retinopathy history.
Mechanism and molecular design
Established: Dulaglutide activates GLP-1 receptors on pancreatic beta cells, increasing cAMP and glucose-dependent insulin release; lower glucagon and slower gastric emptying also improve glucose control. It is a recombinant fusion protein made in Chinese hamster ovary cells, with two identical disulfide-linked chains. Each combines an N-terminal modified GLP-1 analogue, peptide linker and modified human IgG4 Fc. The GLP-1 portion has 90% sequence homology to human GLP-1(7–37); this does not describe the entire 63 kDa fusion. The label says modifications were introduced in regions associated with DPP-4 susceptibility, a potential T-cell epitope, high-affinity Fc-receptor binding and half-antibody formation; it does not quantify the effect of each change. Label §§11–12.
Primary experimental evidence: Glaesner's 2010 abstract reports preserved receptor activity in vitro and insulinotropic activity in islets, followed by rodent/primate experiments. Animal half-life was 1.5–2 days, and monkeys retained enhanced glucose-dependent insulin secretion for up to a week after one dose. These preclinical observations must not replace the label's approximately 5-day human half-life. The accessible abstract does not establish exact residue-by-residue substitutions or partition the human half-life between FcRn recycling, size and protease resistance. PMID 20503261.
Probable design contributors: A larger Fc fusion and resistance to enzymatic inactivation support prolonged exposure; Fc recycling is a plausible contributor. Uncertain in this packet: exact quantitative contributions in humans, detailed glycoform distribution and specific atom-level dulaglutide–receptor contacts. [CITATION NEEDED: full Glaesner engineering methods/sequence figures and a directly inspected dulaglutide-specific FcRn or clearance experiment before quantitative mechanistic attribution.]
Structure panel: PDB 6X18 is a 2.1 Å cryo-EM reference structure of GLP-1 bound to GLP-1R, associated with Zhang et al., PMID 33027691, DOI 10.1016/j.molcel.2020.09.020. It is not a deposited full dulaglutide–Fc/receptor complex. Show the receptor and peptide-binding concept with a clearly separate symbolic Fc diagram; do not graft the fusion into the density as an experimentally solved pose. RCSB 6X18. [VERIFY: molecular figure chain/ligand identity, contact labels and reuse rights before rendering.]
Pathway drawing brief: Draw GLP-1R at the beta-cell membrane, Gs/adenylyl cyclase/cAMP inside, and glucose-dependent insulin secretion downstream. A separate endocrine arrow reduces glucagon/liver glucose output, while a stomach branch shows slowing greatest after initial exposure. Keep REWIND in a distinct measured-outcomes panel. Symbolic arrows must not imply that this diagram proves the mediator of cardiovascular benefit.
Guidance and procedure context
ADA Standards 2026 Section 9 recommends using glucose-lowering drugs with demonstrated cardiovascular benefit in the relevant T2D cardiovascular-risk context, independently of A1c and with or without metformin, while considering individual factors. Recommendation 9.18 discourages combining a DPP-4 inhibitor with GLP-1-based therapy because it adds no glucose-lowering benefit; 9.21 prefers GLP-1-based therapy to insulin for initial/add-on glucose lowering in adults without severe hyperglycemia or crisis. These are professional treatment-framework statements, not directions to change a reader's medicines. ADA 2026 §9.
The 2024 multisociety perioperative guidance uses shared decisions and risk assessment: escalation phase, dose, GI symptoms and other conditions affecting stomach emptying matter. It permits continuation when elevated risk is absent and discusses mitigation when concern exists; the optimal interruption duration remains uncertain. The current Trulicity label itself says data are insufficient to establish a preventive hold interval. Kindel joint guidance, PMID 39370500; label §5.9. The procedure team should make the specific plan.
Class comparison for a discussion, not a switching chart
| Product | Molecular/administration distinction | Evidence useful to compare | Boundary |
|---|---|---|---|
| Trulicity | GLP-1–Fc fusion, weekly subcutaneous single-dose pen | REWIND; AWARD-11; AWARD-PEDS | T2D glycemic indication age 10+; adult CV indication. |
| Ozempic injection | Acylated semaglutide, weekly injection | SUSTAIN and current product-label outcomes | A different molecule/device; match current indication and trial population. |
| Ozempic tablets/Rybelsus | Oral semaglutide with absorption enhancer | SOUL/PIONEER and formulation-specific label | Adult tablet dosing/administration differs from injection and dulaglutide. |
| Mounjaro | Tirzepatide, dual GIP/GLP-1 agonism, weekly injection | SURPASS-CVOT directly used dulaglutide 1.5 mg | Noninferiority is not proven cardiovascular superiority; no 4.5 mg comparison. |
Sources: Trulicity label; Ozempic injection PI; oral label; SURPASS-CVOT. Current comparator sources were inspected in earlier packets; reconfirm before implementation. No equivalence ratio, dose conversion or class-wide indication is implied.
History and discovery
Natural GLP-1 helps the pancreas respond to meals, but its brief action made it difficult to use as a lasting medicine. Wolfgang Glaesner and colleagues at Lilly explored a protein-engineering solution: connect modified GLP-1 segments to an immunoglobulin Fc scaffold. Their 2010 study described LY2189265, the molecule later known as dulaglutide, in cell systems and animal models. It retained receptor activity while lasting longer than the native hormone. FDA first approved Trulicity on September 18, 2014. Development then expanded the evidence beyond lowering blood sugar. REWIND followed adults with type 2 diabetes and cardiovascular disease or risk factors for a median 5.4 years and measured cardiovascular events. AWARD-11 tested higher weekly doses in adults taking metformin, while AWARD-PEDS studied glucose control in young people. Each study answered a different question. Together, they show how a molecular design becomes a medicine through separate tests of exposure, glucose effects, safety and longer-term outcomes.
Sources: Glaesner 2010; FDA Purple Book; REWIND; AWARD-11; AWARD-PEDS.
Diligence: evidence, competition and access
| Question | Dated finding or precise next evidence | Meaning |
|---|---|---|
| Is the target clinically validated? | Receptor/PD evidence plus randomized glucose and CV trials | Target validity does not remove product-specific safety or access risk. |
| What is differentiated? | Weekly Fc fusion, single-dose pen and REWIND population; pediatric glucose evidence | No claim that Trulicity uniquely covers every risk-factor population among current GLP-1 labels. |
| Commercial trajectory? | Lilly 2025 Form 10-K reports Trulicity revenue $4.276 billion (US $2.914 billion; outside US $1.362 billion), versus $5.254 billion in 2024 | Global product revenue, not all-GLP-1 market size or prescription count. |
| US protection? | Lilly's 2025 table estimates 2027 for both US compound patent and biologics data protection; major Europe/Japan compound dates 2029 | Company estimates, not legal clearance or guaranteed biosimilar launch dates. |
| Regulatory database? | Purple Book BLA 125469 lists four Rx autoinjector strengths and discontinued historical prefilled-syringe presentations | A biologic uses Purple Book; it does not disclose all pending applications. |
| Observable use? | CMS lists 617,000 Medicare users and $4,898,378,000 expenditure during November 2024–October 2025 | A dated Medicare population/spend measure, not worldwide demand or manufacturer net revenue. |
| Negotiation? | CMS selected Trulicity for 2028 applicability and confirmed Lilly's participation in March 2026 | No 2028 negotiated price or individual copay is invented. |
| Current price example? | LillyDirect advertises starting $389 for a monthly supply, defined as four pens: arithmetic $97.25/pen before possible tax/fees | Self-pay offer, not WAC, insurance price, pharmacy-stock guarantee or lowest-price comparison. |
Sources: Lilly 2025 Form 10-K; Purple Book; CMS 2028 fact sheet; CMS participation; LillyDirect; purchase terms. Checked 2026-10-18.
The self-pay terms require age 18+, residence in the US/Puerto Rico and a prescription for an approved use. Purchases cannot be submitted for insurance reimbursement or counted toward a deductible, out-of-pocket requirements or Medicare Part D TrOOP. Thus pediatric drug labeling does not imply eligibility for this adult offer. The separate manufacturer pricing page's numeric WAC did not load in the retrieved view; it is not inferred from the self-pay offer. Recheck price and eligibility at dispensing. No exact patent date, pending biosimilar filing or product-development budget is guessed.
Common misconceptions
| Misconception | Correction |
|---|---|
| “An Fc tail means it attacks immune cells.” | Its intended therapeutic target is GLP-1R; Fc is part of the engineered protein design. |
| “Five-day half-life means it leaves the body on day five.” | Half-life describes concentration decline, not complete removal or a switch date. |
| “Every GLP-1 product is approved for weight loss.” | Trulicity's current indications are T2D glucose control and specified adult CV risk reduction. |
| “Less hunger means the heart is protected.” | Heart outcomes were measured in REWIND; appetite is not a personal protection test. |
| “The missed dose must be taken within three days after it was due.” | The label threshold is at least 72 hours remaining until the next scheduled dose. |
| “An A1c benefit proves a BMI or CV benefit in children.” | AWARD-PEDS supports glucose control; it did not demonstrate a BMI benefit or pediatric CV outcomes. |
| “A genotype or receptor picture predicts my dose.” | No genotype-based dosing or individual response model is established by these sources. |
| “Patent expiry guarantees a cheaper product that day.” | Regulatory approval, litigation, manufacturing, launch and coverage remain separate. |
Sources: label §§1–2, 11–12, 14; primary trials and Purple Book linked above.
Eight questions to ask your pharmacist
- Which Trulicity pen strength is on my prescription, and can you show me that exact device?
- How does my care team's plan handle a missed dose or a change of weekly day?
- Could insulin or another medicine increase my risk of low blood sugar?
- Do any oral medicines I take need extra checks because stomach emptying slows?
- Which belly, fluid-loss, allergy or vision symptoms need urgent help?
- What should I tell the team before anesthesia or deep sedation?
- How should I track the total time my pen has been outside the fridge?
- What will this exact prescription cost through my plan, and how do self-pay terms differ?
Review and open items
[VERIFY: final current label/version, approval/history dates, source-lock of 2026 guideline wording and all dated commercial/IP/Medicare/price facts before publication.] [VERIFY: full engineering sequence/FcRn evidence, receptor figure contacts, scientific and device-visual review, trial-estimand reconciliation and native-language/comprehension checks.] [FOUNDER TO SUPPLY: actual qualified clinical reviewer and native Spanish health-professional review records; do not mark these drafts reviewed without them.]
Decisions made for the founder: preserve label population classifications and actual interval rules; separate rounded from exact-count NNT, surrogate from clinical outcomes and paper from label analyses. Use current 2025 corporate protection estimates rather than obsolete 2026 data-protection shorthand; show a dated offer with terms rather than fabricate WAC. Keep all drafts local pending independent review. No new live SAFETY FLAG established.
Reference pack
Source codes in the text resolve to the references below. Retrieval and clinical-review status are distinct.
Primary source responses, access status, bytes, hashes and local paths are in evidence/receipt.json. Readable label and AWARD-11 extracts are under evidence/readable/; fetch script is evidence/fetch_sources.py. Source identities were checked against metadata before article-specific claims. Parent-retained sources are identified as such.
| Group / ID | Citation and URL | Checked scope and limits |
|---|---|---|
| LABEL | DailyMed Trulicity US prescribing information, set ID 463050bd-2b1c-40f5-b3c3-0a04bb433309 | Current SPL v62 retrieved as XML and HTML; effective 2026-06-16; label says revised 03/2026. Nested sections/tables extracted. Raw hashes in receipt. |
| LABEL-HISTORY | DailyMed SPL history API | Current and prior versions/dates retained; history is not itself clinical interpretation. |
| LILLY-PI | Lilly Trulicity US prescribing information PDF | Downloaded current company PI and compared with the retrieved DailyMed labeling. DailyMed SPL is the selected current-label record. |
| FDA-BLA | Drugs@FDA, BLA 125469 | FDA application record inspected. Parent separately verified SUPPL-65 action dated 2026-03-12 and original BLA approval 2014-09-18 via Purple Book product record. Regulatory dates do not establish exclusivity or generic entry. |
| FDA-S065 | FDA supplement S-065 action letter, BLA 125469 | FDA letter dated 2026-03-12 adds postmarketing intestinal obstruction and severe constipation, including fecal impaction, to label §§5.6 and 6.2. Voluntary reports do not establish incidence or causality. |
| GLAESNER | Glaesner et al. Engineering and characterization of the long-acting GLP-1 analogue LY2189265. PMID 20503261; DOI 10.1002/dmrr.1080 | Europe PMC metadata/abstract identity checked. Wiley full text not retained/read in this bundle; exact sequence mutations and detailed experimental claims remain unverified. |
| Bjerre-Knudsen | Bjerre-Knudsen et al. GLP-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. PMID 20203154 | Rodent thyroid C-cell study; not human brown-adipose evidence or a dulaglutide-specific clinical outcome. |
| PDB-6X18 | RCSB PDB 6X18 | RCSB API metadata retained; GLP-1–GLP-1R–Gs complex. Ligand is GLP-1, not dulaglutide; use only with this scope. |
| REWIND | Gerstein et al. REWIND, PMID 31189511; DOI 10.1016/S0140-6736(19)31149-3 | Europe PMC abstract record identity retained; label §14.5 supplies current trial population and table values. Full article not retained in this bundle. |
| REWIND-EMA | EMA assessment report for dulaglutide variation | Parent-retained primary regulatory assessment, retrieved PDF. Confirms baseline REWIND 31.5% established CVD, 62.8% confirmed without CVD and with multiple risk factors, 5.7% unclassified. Does not support calculating 68.5% eligible primary-prevention patients. |
| AWARD-11 | Frias et al. AWARD-11, PMID 33397768; PMCID PMC7896253; DOI 10.2337/dc20-1473; full text | Europe PMC matched PMID/PMCID/DOI metadata; full XML retrieved/read. Adult dose-comparison trial, 36-week primary time point, add-on to metformin. Match every efficacy number to its stated estimand/timepoint. |
| AWARD-PEDS | Arslanian et al. AWARD-PEDS, PMID 35658022; DOI 10.1056/NEJMoa2204601 | DOI/PMID identity matched; NEJM abstract inspected. Current label §14.6 is separately retained. The label presents pooled target attainment 52% vs14%; abstract says approximately 51% vs14%; preserve source convention. An unrelated PMID returned by an exploratory query is quarantined and excluded in the receipt. |
| SURPASS-CVOT | Nicholls et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide, PMID 41406444; DOI 10.1056/NEJMoa2505928 | Europe PMC matched DOI/PMID metadata. Parent-retained primary abstract identifies dulaglutide 1.5 mg comparator, tirzepatide HR .92, 95.3% CI .83–1.01, and noninferiority. Do not convert to superiority; label and paper analysis denominators differ. |
| ADA26-9 | ADA Standards of Care 2026 §9, PMID 41358900; PMCID PMC12690185; DOI 10.2337/dc26-S009 | Parent-read recommendation context: §9.18 discourages DPP-4 inhibitor plus GLP-1-based therapy; §9.21 prefers GLP-1-based therapy to insulin absent severe hyperglycemia/crisis; the CVD-risk paragraph supports use independent of A1c and with/without metformin while considering person-specific factors. Not a patient-specific direction. |
| ADA26-10 | ADA Standards of Care 2026 §10, PMID 41358899; PMCID PMC12690187; DOI 10.2337/dc26-S010 | Exact article metadata/DOI checked. Full recommendation text and grades not reviewed in this evidence pass. |
| KINDel-PERIOP | Kindel et al. joint multisociety guidance, PMID 39370500; PMCID PMC11666732; DOI 10.1007/s00464-024-11263-2; parallel journal publication metadata, PMID 39482213 | Parent-retained/read full text: shared risk assessment, continuation when elevated risk is absent, individualized mitigation when concern exists; optimal hold duration remains unknown. The PMID 39482213 record was metadata-only. Not a universal hold instruction. |
| MEDLINEPLUS | MedlinePlus dulaglutide drug information | Page retrieved to raw HTML; consumer source for plain-language cross-check, not replacement for the label. |
| LILLY-SEC | Eli Lilly 2025 Form 10-K | Parent web-verified; local retrieval was blocked (HTTP 403), so no local readable filing copy is claimed. Filing reports 2025 US sales $2.914bn and outside-US sales $1.362bn; it lists compound US and US biologic exclusivity through 2027 and EU/Japan compound exclusivity through 2029. These are company-reported/date-specific, not a generic-entry forecast. |
| CMS-MFP | CMS 2028 selected-drug fact sheet; manufacturer participation fact sheet | Parent-retained facts: dulaglutide selected Jan. 27 and manufacturer participation announced Mar. 13, 2026. The selected-drug fact sheet reports 617,000 Medicare enrollees and $4.898378bn Part B/D expenditures for Nov. 2024–Oct. 2025. These are specified-period Medicare figures, not worldwide market size. |
| LILLYDIRECT | LillyDirect Trulicity; purchase terms | Parent web-checked public page and terms: advertised $389/month across four strengths, subject to eligibility and other terms. Terms describe four pens, age 18+, US/Puerto Rico, prescription for an approved use, no insurance submission, and no deductible or Part D TrOOP credit; taxes/fees may apply. Local page retrieval returned HTTP 403/challenge content, not a readable copy. Not net price or guaranteed availability. |
Deferred: complete Glaesner paper review; ADA §10 recommendation review; legal interpretation of patent/exclusivity and biosimilar entry; external clinical review. The source bundle does not establish medical sign-off.
Editorial review notes
Marked verification items remain unresolved. Source checks and reading-grade checks do not constitute clinical approval.
Claim-by-claim accuracy check
Scope: current US dulaglutide (Trulicity) label, core trial and mechanism source identities, and parent-verified commercial/regulatory records. The current inspected DailyMed SPL is version 62, effective June 16, 2026; it says Revised March 2026. This is an evidence check for drafting, not clinical review or publication approval. Detailed source scope is in #references and SOURCE-MEMO.md.
| Priority | Audit or draft proposition | Checked correction or boundary | Source |
|---|---|---|---|
| P0 | Audit describes missed dose as “within 3 days.” | Replace with the label's exact condition: use the missed dose as soon as possible if at least 3 days/72 hours remain until the next scheduled dose; if fewer than 3 days remain, skip and take the next dose on its regular day. “Within 3 days of a missed dose” reverses or obscures the reference point. | Current label §2.3 |
| P0 | REWIND baseline description uses “68.5% without established CVD.” | Current label §14.5 specifies 31.5% with established CVD and 62.8% confirmed without established CVD but with multiple risk factors; another 5.7% are not categorized in those descriptions. Do not calculate the latter group as 100−31.5 or treat it as primary-prevention eligible. EMA assessment confirms the split. | Current label §14.5; EMA REWIND assessment |
| P0 | REWIND effect is sometimes framed as the only GLP-1 cardiovascular label or as unique proof of primary prevention. | State the actual Trulicity population and label language: adults with type 2 diabetes and established CVD or multiple risk factors. The population wording differs from Victoza's established-CVD language, but dulaglutide is not the only GLP-1 product with a cardiovascular-risk label. Avoid broad class exclusivity. | Current Trulicity label §1; Ozempic injection prescribing information §1, inspected in the earlier Ozempic packet; final comparator source-lock remains required |
| P0 | Retinopathy signal is attributed to rapid glucose lowering as a demonstrated dulaglutide mechanism. | Label §5.7 reports 1.9% vs 1.5% overall, 8.5% vs 6.2% among those with baseline retinopathy, and 1% vs 1% without known history. It says rapid glucose improvement has been associated with temporary worsening; the label does not establish that this caused the observed arm difference. Say monitor people with retinopathy history; do not claim causal proof. | Current label §5.7 |
| P0 | 3 mg and 4.5 mg bioavailability may be stated as directly measured or equivalent to 1.5 mg. | Label §12.3 says bioavailability was measured at 0.75 mg (65%) and 1.5 mg (47%); values for 3/4.5 mg were estimated similar to 1.5 mg and were not specifically studied. Tmax at steady state 24–72 h (median 48), steady state 2–4 weeks, half-life about 5 days. Volumes 3.09/5.98 L and clearance 0.142 L/h are apparent population estimates. | Current label §12.3 |
| P1 | Dosing can be compressed into a generic “increase every 4 weeks” instruction. | Quote label boundaries: adult .75 mg weekly, may rise to 1.5 mg after 4 weeks; additional 1.5 mg increments only after at least 4 weeks on current dose, maximum 4.5 mg. Pediatric patients start .75 mg and may increase to maximum 1.5 mg after at least 4 weeks. Keep label description separate from an individual prescription. | Current label §§2.1–2.2 |
| P1 | AWARD-11 or pediatric efficacy figures are presented without identifying source/timepoint. | AWARD-11 is an adult 36-week add-on-to-metformin dose-comparison trial. Current label §14 values include HbA1c changes −1.5/−1.6/−1.8 percentage points and weight changes −3.0/−3.8/−4.6 kg at 1.5/3/4.5 mg. For AWARD-PEDS, the label says 52% pooled dulaglutide vs 14% placebo reached HbA1c <7%; NEJM abstract reports approximately 51% vs 14%. Retain source-specific presentations; do not silently reconcile. | Current label §§14.3, 14.6; Frias PMID 33397768; Arslanian PMID 35658022 |
| P1 | PDB 6X18 is described as dulaglutide-bound or as a whole Trulicity structure. | 6X18 is a GLP-1 peptide–GLP-1 receptor–Gs complex; it does not contain dulaglutide. It can support a receptor-binding illustration for the GLP-1 moiety with that limitation stated. | RCSB 6X18 |
| P1 | Exact dulaglutide residue substitutions or Fc effects are stated as established from the supplied audit. | Glaesner PMID 20503261 identity/abstract is verified; full paper figures were not read here. Keep exact substitutions such as Ala8→Gly, Gly22→Glu, Arg36→Gly marked for confirmation. Label §11 says modifications were introduced in regions responsible for high-affinity Fc-receptor binding and half-antibody formation; do not claim measured elimination or reduction of all Fc interactions. | Label §11; Glaesner 2010 abstract scope |
| P1 | SURPASS-CVOT is used as head-to-head evidence that dulaglutide is inferior or superior to tirzepatide. | It used dulaglutide 1.5 mg as active comparator. Parent-verified abstract reports tirzepatide HR .92 (95.3% CI .83–1.01) and noninferiority; preserve the paper's 95.3% CI and note article/label analysis denominator differences. Do not convert a noninferiority result to superiority or a general class ranking. | Nicholls PMID 41406444; DOI 10.1056/NEJMoa2505928 |
| P2 | Dated market or exclusivity details are treated as current guarantees. | Parent-verified sources support 2025 Lilly sales and dated self-pay offer, CMS selected-drug facts, current LillyDirect advertised cash price, and a Purple Book BLA record. These are source- and date-specific; no inference about realized net price, pharmacy stock, patent scope, or guaranteed biosimilar entry. | Lilly SEC 2025 10-K; CMS fact sheet; LillyDirect; FDA Purple Book |
| P1 | Postmarketing severe gastrointestinal events are omitted from the summary. | FDA supplement S-065 dated 2026-03-12 adds intestinal obstruction and severe constipation, including fecal impaction, to §§5.6/6.2. Voluntary reports do not establish incidence or causality. | FDA S-065 letter; current label §§5.6, 6.2 |
Explicit source limitations
ADA Standards of Care 2026 §9 recommendation context was parent-read from full text; §10 was metadata-only, so no §10 recommendation is claimed. The parent retained/read the full joint perioperative guidance with PMID 39370500/PMCID PMC11666732; the parallel PMID 39482213 record was metadata-only. Glaesner full text was not available in the source bundle; detailed mutation claims remain pending paper-level verification. Parent retains interpretation of SURPASS-CVOT and commercial facts. No item here is a clinical sign-off.
Plain-language checks
Verbatim before text comes from the dated published-page dossier; after text is saved local draft Markdown. Body counts use the packet validator expression and Flesch–Kincaid grades use textstat. Mechanical readability does not establish comprehension, clinical review or a live change.
Ten introductions — actual before and after
| Role | Before words / FK | After words / FK |
|---|---|---|
| Patient | 54 / 11.32 | 116 / 5.62 |
| Caregiver | 43 / 11.68 | 104 / 5.94 |
| Pharmacist | 38 / 14.5 | 96 / 10.78 |
| Clinician | 49 / 16.55 | 86 / 9.17 |
| Nurse | 39 / 16.71 | 94 / 11.24 |
| Student | 44 / 11.32 | 94 / 10.58 |
| Scientist | 40 / 17.34 | 92 / 11.85 |
| Chemist | 45 / 13.86 | 94 / 15.72 |
| Investor / Diligence Analyst | 44 / 20.43 | 97 / 11.75 |
| General | 44 / 12.12 | 96 / 8.2 |
Patient and Caregiver after bodies target FK ≤8; General targets 8–10. Professional grades are reported rather than forced to a public score. Limits, Safety, Role evidence and Sources are excluded from body scoring.
Patient
Before (54 words; FK 11.32): Trulicity activates GLP-1 receptors to help the pancreas release insulin when blood sugar is high. It also reduces glucagon, a signal that tells the liver to release sugar, and slows food leaving the stomach. These actions lower blood sugar; its heart-risk benefit is supported by clinical studies in certain adults with type 2 diabetes.
After (116 words; FK 5.62): Trulicity acts on GLP-1 receptors in the pancreas. When blood sugar is high, this helps the body release insulin and send less of a signal that raises sugar. It is a weekly shot, not insulin. A 36-week study found average A1c drops of about 1.5 to 1.8 points across three studied doses. A1c is a long-term blood sugar test. Your own change may differ. In a heart study of adults with type 2 diabetes and heart disease or risk factors, about 12 in 100 on Trulicity had death from heart or blood vessel disease, a heart attack or a stroke, versus about 13 in 100 on placebo over 5.4 years. It is not a weight-loss approval.
Caregiver
Before (43 words; FK 11.68): Dulaglutide helps coordinate glucose-responsive insulin release and reduces signals that raise glucose. It is not insulin, and combining it with insulin or certain tablets can still cause low glucose. Follow response and symptoms rather than assuming every GLP-1 medicine has the same benefits.
After (104 words; FK 5.94): Dulaglutide works on GLP-1 receptors in the pancreas. It helps the body release insulin when blood sugar is high. A weekly Trulicity pen is not insulin. Watch for nausea, poor appetite, low fluid intake and vomiting. Write down the shot day, pen strength and sugar readings if the care team asks. This matters more when the person also uses insulin or a pill that raises insulin. Call the care team for lasting belly pain, trouble drinking, a new vision problem or signs of low sugar. In one group, 21.1% of adults using 1.5 mg reported nausea; this is not a forecast for one person.
Pharmacist
Before (38 words; FK 14.5): Dulaglutide activates GLP-1 receptors coupled to adenylyl cyclase, raising beta-cell cAMP and promoting glucose-dependent insulin release. It also reduces glucagon secretion and delays gastric emptying. The delay can affect oral-medication absorption, while its Fc-fusion design supports prolonged exposure.
After (96 words; FK 10.78): Dulaglutide activates pancreatic GLP-1 receptors, raising beta-cell cAMP and glucose-dependent insulin secretion; reduced glucagon and slower gastric emptying add to glycemic effects. The Fc-fusion protein has a half-life of about five days, so reconcile duplicate GLP-1 therapy and the exact weekly pen before counseling. The adult label describes 0.75, 1.5, 3 and 4.5 mg strengths with staged escalation, rather than interchangeable pens. Gastric delay can alter the absorption rate of some oral medicines; assess drugs with narrow monitoring needs. A missed dose is label-eligible only when at least 72 hours remain before the next scheduled dose.
Clinician
Before (49 words; FK 16.55): Trulicity lowers glucose through glucose-dependent insulin secretion, reduced glucagon and delayed gastric emptying. REWIND demonstrated a reduction in the primary cardiovascular composite in adults with type 2 diabetes and cardiovascular disease or risk factors. That endpoint benefit should not be described as proof of a single molecular cardiovascular mechanism.
After (86 words; FK 9.17): Dulaglutide stimulates islet GLP-1 receptors, increasing glucose-dependent insulin and reducing glucagon; this lowers HbA1c without identifying the mechanism of cardiovascular benefit. In REWIND, 9,901 adults with type 2 diabetes were followed a median 5.4 years; 31.5% had established cardiovascular disease. MACE occurred in 12.0% versus 13.4%, HR 0.88 (95% CI 0.79–0.99). AWARD-11 measured 36-week HbA1c changes of −1.5, −1.6 and −1.8 points at 1.5, 3 and 4.5 mg. Interpret those glycemic surrogates separately from REWIND, and review baseline retinopathy, GI tolerance and concomitant hypoglycemia risk.
Nurse
Before (39 words; FK 16.71): Trulicity strengthens the insulin response to elevated glucose and slows stomach emptying. Gastrointestinal symptoms, hydration and glucose should be considered together when assessing tolerability. Patients with a retinopathy history need appropriate monitoring because the label includes a retinopathy-complication warning.
After (94 words; FK 11.24): Trulicity stimulates GLP-1 receptors in pancreatic beta cells, helping insulin rise when glucose is high. The weekly single-dose pen changes what to assess: confirm the prescribed device and use teach-back with its instructions rather than assuming the pen is reusable. Track glucose patterns, appetite, nausea, vomiting and hydration; delayed gastric emptying can affect how food and oral medicines move. Ask about a retinopathy history and report new vision changes. The label recorded retinopathy complications in 1.9% on Trulicity and 1.5% on placebo in REWIND, an observation that calls for monitoring, not a causal diagnosis.
Student
Before (44 words; FK 11.32): GLP-1 is an incretin that helps beta cells respond to glucose. Dulaglutide activates the same receptor, increasing cAMP signaling and insulin release when glucose is elevated. Its modified peptide–Fc fusion affects how long the drug persists, rather than turning it into an insulin molecule.
After (94 words; FK 10.58): Dulaglutide binds class B GLP-1 receptors on pancreatic beta cells. Gs activates adenylyl cyclase, raising cAMP and amplifying glucose-dependent insulin secretion; reduced glucagon limits the liver's glucose-release signal. The molecule joins modified GLP-1 analogues to an IgG4 Fc scaffold, making a roughly 63 kDa protein with an approximately five-day terminal half-life. Those design features change exposure, not the identity of the receptor target. Gastric-emptying delay can slow oral-drug absorption, while insulin or sulfonylureas can still cause hypoglycemia. In a 36-week dose study, average HbA1c changes ranged from −1.5 to −1.8 points across studied strengths.
Scientist
Before (40 words; FK 17.34): The label separates receptor-mediated beta-cell cAMP effects from measured changes in glucose, glucagon and gastric emptying. REWIND supplies randomized cardiovascular endpoint evidence, not direct identification of all mediating pathways. Exploratory organ outcomes must not be promoted to unlisted product indications.
After (92 words; FK 11.85): The target is islet GLP-1R: dulaglutide raises beta-cell cAMP and supports insulin secretion at elevated glucose. Glaesner and colleagues engineered a GLP-1 analogue–IgG4 Fc fusion to extend activity; the current label documents a roughly five-day human half-life, while the engineering experiments are a different evidence tier. REWIND supplies randomized endpoint evidence, HR 0.88, in a group mostly without established cardiovascular disease. Retinopathy complications were 1.9% versus 1.5%; the label links rapid glucose improvement with temporary worsening in general, but does not prove that mechanism caused this imbalance. Mediation of MACE remains open.
Chemist
Before (45 words; FK 13.86): Dulaglutide comprises two modified GLP-1 analogue chains linked to a modified human IgG4 Fc region. The GLP-1 segment is engineered to resist DPP-4-related degradation, and the fusion supports prolonged exposure. The Fc-containing molecule is used as a receptor agonist, not as an immune-targeting antibody treatment.
After (94 words; FK 15.72): Dulaglutide is a roughly 63 kDa protein assembled from two identical, disulfide-linked chains, each joining a modified GLP-1 analogue to a modified human IgG4 Fc region. The GLP-1 parts activate pancreatic GLP-1R; the Fc scaffold supports an approximately five-day elimination half-life without making this an immune-targeting antibody. The label describes Fc modifications in regions related to high-affinity Fc-receptor binding and half-antibody formation. These features matter for architecture and persistence, while glucose-dependent insulin release is the functional readout. Show peptide, linkers, Fc and disulfides separately; PDB 6X18 illustrates GLP-1 receptor geometry, not dulaglutide's bound pose.
Investor / Diligence Analyst
Before (44 words; FK 20.43): Trulicity combines long-acting GLP-1 receptor agonism with glycemic and cardiovascular outcome evidence. Its cardiovascular label includes established disease or multiple risk factors in adults with type 2 diabetes, a distinction from Victoza's established-disease wording. Molecular similarity does not establish interchangeable indications or comparative superiority.
After (97 words; FK 11.75): Trulicity's weekly GLP-1R agonism reaches pancreatic islets and has both glycemic and outcome evidence. REWIND enrolled 9,901 adults with type 2 diabetes; 31.5% had confirmed established cardiovascular disease, while a majority had multiple risk factors. MACE was 12.0% versus 13.4% over median 5.4 years, HR 0.88. That population supports the US label's established-disease-or-multiple-risk-factor wording; it does not prove a unique class benefit. Dulaglutide 1.5 mg served as the active comparator in SURPASS-CVOT against tirzepatide, so compare endpoint designs and populations before drawing competitive conclusions. Fc design supports weekly delivery but does not alone establish market durability.
General
Before (44 words; FK 12.12): Trulicity activates GLP-1 receptors, helping the pancreas release insulin when blood sugar is high. It also reduces the signal for the liver to release sugar and slows stomach emptying. Its long-lasting action supports glucose control; its specific heart-risk benefit comes from clinical outcome studies.
After (96 words; FK 8.2): Trulicity acts on GLP-1 receptors in the pancreas, where it helps the body release insulin when blood sugar is high. It also reduces glucagon, a signal that makes the liver release sugar, and slows early stomach emptying. Its surprising feature is an Fc protein tail that helps the medicine last for a weekly shot, without making it an immune attack drug. In a 36-week study, average A1c fell by 1.5 to 1.8 points at three studied doses. A separate heart study measured fewer major events in eligible adults, but did not explain a single protective pathway.
Two Patient FAQ comparisons
The original page has shared FAQ answers; the local after versions are targeted Patient repairs with matched question intent. The comparison is not an assertion that every original fact was wrong.
Who is Trulicity labeled for? → Why might it be prescribed for me?
Before (45 words; FK 16.79): For glucose control, adults and children aged 10 years and older with type 2 diabetes, with diet and exercise. Its cardiovascular indication is for adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors; it does not automatically apply to children.
After (77 words; FK 6.27): A prescriber may suggest dulaglutide to help manage type 2 diabetes. For some adults with diabetes, it can also lower the chance of major heart problems. The label covers adults with heart disease or more than one heart risk. It does not mean everyone with diabetes needs this drug. The choice depends on your health, other drugs, side effects, and goals. Ask your prescriber what reason applies to you and how you will check if it helps.
Which symptoms need urgent assessment? → Which symptoms need urgent help?
Before (35 words; FK 11.89): Severe persistent abdominal pain may indicate pancreatitis; upper-abdominal pain with fever or jaundice may indicate gallbladder disease. Seek emergency help for breathing difficulty or face or throat swelling. This is not the complete warning list.
After (81 words; FK 5.55): Get urgent help for trouble breathing or swelling of the face, lips, tongue, or throat. Severe belly pain that does not stop may be pancreatitis and needs prompt care. Call the care team about ongoing vomiting or diarrhea, which can dry you out and harm the kidneys, or a new change in sight. The boxed thyroid warning comes from tumors in rats. It is not known if people have the same risk. Report a neck lump, trouble swallowing, or lasting hoarseness.
Narration and engagement measurements
The original six-chapter product data had two prose templates distributed across ten roles. The local 07 draft supplies 60 distinct scripts with the same six titles, each targeted to 40–70 words. Visual specifications are proposed only.
05 REWIND Patient summary: 41 words; FK 7.75.
Verbatim: Over about five years, a heart attack, stroke or death from heart disease occurred in about 120 per 1,000 adults on the drug. About 134 per 1,000 on placebo had one of these events; both groups had usual care.
05 AWARD-11 Patient summary: 43 words; FK 3.45.
Verbatim: At 36 weeks, about 50 in 100 adults on the 1.5 mg dose reached an A1c below 7%, versus 56 on 3 mg and 62 on 4.5 mg. All took metformin, and this blood sugar goal is not a test of heart risk.
05 AWARD-PEDS Patient summary: 37 words; FK 7.89.
Verbatim: At 26 weeks, about 52 in 100 youths on the drug reached an A1c below 7%, versus 14 on placebo, the label says. The study found better blood sugar control but no benefit for body mass index.
05 SURPASS-CVOT Patient summary: 41 words; FK 7.55.
Verbatim: In the trial, a heart attack, stroke or heart-related death occurred in about 122 per 1,000 on tirzepatide, versus 131 on dulaglutide. The study met its set test for being no worse, but did not prove that tirzepatide was better.
05 discovery history: 151 prose words; FK 11.1.
Verbatim prose: Natural GLP-1 helps the pancreas respond to meals, but its brief action made it difficult to use as a lasting medicine. Wolfgang Glaesner and colleagues at Lilly explored a protein-engineering solution: connect modified GLP-1 segments to an immunoglobulin Fc scaffold. Their 2010 study described LY2189265, the molecule later known as dulaglutide, in cell systems and animal models. It retained receptor activity while lasting longer than the native hormone. FDA first approved Trulicity on September 18, 2014. Development then expanded the evidence beyond lowering blood sugar. REWIND followed adults with type 2 diabetes and cardiovascular disease or risk factors for a median 5.4 years and measured cardiovascular events. AWARD-11 tested higher weekly doses in adults taking metformin, while AWARD-PEDS studied glucose control in young people. Each study answered a different question. Together, they show how a molecular design becomes a medicine through separate tests of exposure, glucose effects, safety and longer-term outcomes.
Review limit
Public reading grades are editorial screens. Before release, verify current label version, pen/device content, completed FAQ text, emergency phrasing, clinical review and Spanish review against the exact final page. No live text or audio has been changed.
Changes and acceptance checks
Draft changes and evidence boundaries
| Output | Change | Evidence limit |
|---|---|---|
| 00–02 | Retained current US SPL, audited historical claims and 21 grouped primary/regulatory references. | Current DailyMed version 62 has a March 2026 label revision and June 16, 2026 SPL effective date; source access and retrieval scope are logged in the evidence memo. |
| 03 | Ten 60–120-word mechanism-led role introductions plus separate Limits, Safety, Role evidence and Sources. | Patient/Caregiver/General saved body FK grades meet the public targets. Boxed thyroid warning and all formal contraindications appear in Patient, Pharmacist, Clinician and Nurse sections. |
| 04 | Ninety-four targeted perspective FAQ replacements are saved across ten roles. | The parent is completing three remaining General-answer grade repairs; final public readability is determined from the saved Markdown. |
| 05 | Parent-owned mechanism, outcomes, safety, history and market blocks tie trial numbers to the labeled populations. | Four two-sentence natural-frequency summaries were repaired and saved at FK 7.75/3.45/7.89/7.55; the source-linked history is 151 prose words. No live page change is implied. |
| 06 | Verbatim dossier-before versus saved-03-after text, two saved Patient 04 FAQ comparisons and saved 05 patient-summary measurements. | The FAQ comparisons were refreshed from the current saved 04. Textstat is an editorial screen, not comprehension or clinical approval. |
| 07 | Six original chapter titles retained, with 60 distinct 40–70-word narrations and a proposed pathway/visual plan. | PDB 6X18 contains GLP-1 bound to GLP-1R–Gs, not dulaglutide; no animation or recording is live. |
| 08 | Spanish Patient seed tracks the exact saved English source and records terminology, back-translation and review gates. | Native Spanish-speaking health-professional and independent clinical approvals remain pending. |
Corrections to the audit or source interpretation
- REWIND randomized 9,901 adults. Current label §14.5 reports 31.5% with established CVD and 62.8% without established CVD but with multiple risk factors; 5.7% were not classified in either reported group. Do not call the arithmetic complement of 31.5% a fully documented primary-prevention subgroup.
- REWIND primary MACE counts are 594/4,949 versus 663/4,952, HR 0.88 (95% CI 0.79–0.99) over median 5.4 years. Exact crude ARR is about 1.386 percentage points and reciprocal ceiling NNT 73; subtracting rounded 12.0% versus 13.4% gives 1.4 points and reciprocal ceiling 72. Neither is a survival-adjusted fixed-time NNT.
- The audit's “missed dose within 3 days” shortcut is ambiguous. Label §2.3 permits a missed injection only when at least 72 hours remain until the next scheduled dose; otherwise it describes skipping. Drafts report the label condition and route personal timing to the care team.
- The 1.9% versus 1.5% retinopathy-complication observation does not prove dulaglutide caused a specific retinal injury mechanism or that rapid A1c improvement mediated the trial imbalance.
- Current label §14.3, not §14.4, contains the AWARD-11 36-week add-on-to-metformin comparison. Its mean HbA1c changes are −1.5/−1.6/−1.8 percentage points at 1.5/3/4.5 mg; glycemic outcomes are distinct from REWIND's clinical composite.
- Dulaglutide is an engineered GLP-1 analogue–IgG4 Fc fusion. Current label supports two disulfide-linked chains, roughly 63 kDa and about five days of terminal half-life. Glaesner's abstract was checked but full engineering figures were not retained; exact residue substitutions are marked for verification. PDB 6X18 is not a dulaglutide-bound structure.
- The label covers glucose control from age 10 and adult MACE-risk reduction in specified type 2 diabetes populations. Neither a weight-management nor separate kidney-outcomes indication follows. The pediatric label maximum differs from the adult escalation range; drafts do not provide individual dosing advice.
- To keep role bodies within 60–120 words, 03 places adult versus pediatric escalation and maximum-strength distinctions in an adjacent Pharmacist Role evidence line, current ADA 2026 §9 and SURPASS-CVOT noninferiority context in an adjacent Clinician Role evidence line, and strength-specific single-dose pen/site/no-separate-priming details in an adjacent Nurse Role evidence line. These are source-linked professional context, not individual instructions.
- Lilly's 2025 Form 10-K product revenue and estimated 2027 US compound-patent/biologics-data dates, Purple Book BLA entry, CMS figures and LillyDirect offer are dated, source-specific diligence inputs. The offer is not WAC or typical insured cost; an estimated protection date is not a guaranteed biosimilar launch. Dated claims require a publication-time recheck.
- Parent 05 typography repair restored numeric spacing without changing scientific identifiers, removed temporary token artifacts, and replaced all four patient trial summaries with two-sentence wording that preserved the original endpoint, comparison group and trial scope. Saved 06 records the final text and FK scores, including the 151-word discovery history.
Audit §7 acceptance check — saved draft
| Audit item | Status | Result or adaptation |
|---|---|---|
| REWIND HR, percentages and population split | Pass in draft | 03/07 and parent-owned 05 retain 12.0% versus 13.4%, HR 0.88 and classified 31.5%/62.8% label groups; 5.7% unknown category is preserved. |
| AWARD-11 dose-response | Pass in draft | 03 and 05 use the label §14.3 36-week HbA1c means; the study is not treated as a cardiovascular-outcome trial. |
| Ten 60–120-word target/tissue/clinical-number introductions | Pass in draft | Saved 03 has ten role bodies; measured table reports words, FK grade and decision supported. Public-target grades pass. |
| Forty-two distinct role chapter sentences | Exceeded in draft | 07 has 60 unique 40–70-word scripts, one per original chapter for each of ten roles; openings and decisions differ, rather than reusing one professional template. |
| Unverified claims labeled | Pass in draft | Figure-level fusion details, ADA wording, future price, stock, biosimilar filings and protection dates have explicit scope or [VERIFY] notes. |
| No invented numbers | Pass subject to final source lock | Trial denominators, label PK, adverse-event rates and dated commercial numbers are tied to primary sources; exact versus rounded arithmetic remains separate. |
| Patient FAQ and translation checks | Draft complete; final packet grade check in progress | Ninety-four saved FAQ repairs and the matched Spanish Patient seed exist. The parent is completing General-answer grade repairs; Spanish back-translation and native health-professional review remain pending. |
Outstanding review
[VERIFY: current SPL version at implementation; full ADA 2026 recommendation wording; Glaesner sequence/figure-level claims; 6X18 visual rights and construct limits; all dated patent, Purple Book, Lilly revenue, CMS, self-pay price and availability statements; merged-page role selector, disclaimer count, device animation, accessibility and patient comprehension.] [FOUNDER TO SUPPLY: named clinical reviewer and native Spanish-speaking health-professional reviewer, with dates and records tied to the exact final page version.]
This record documents local drafts only. It does not approve a translation, clinical content, animation, audio, outreach or publication.
Final saved-artifact closeout
Parent canonical validation: ten introductions, 94 FAQs across all ten roles, 60 unique chapter scripts, zero word-count/readability/role-count failures. Final General FAQ repairs were checked from saved Markdown. All 00–08 draft files are complete. Clinical, native-language and live implementation checks remain open; this is a local drafting milestone only.
Translation draft — native clinical review pending
This is a local Spanish editorial seed for the US dulaglutide single-dose pen. It follows the saved English Patient body, Limits and Safety in 03. The English source and current US label control the claims. It is neither a live translation nor an individual injection or missed-dose instruction.
English source — exact saved 03 Patient text
Trulicity acts on GLP-1 receptors in the pancreas. When blood sugar is high, this helps the body release insulin and send less of a signal that raises sugar. It is a weekly shot, not insulin. A 36-week study found average A1c drops of about 1.5 to 1.8 points across three studied doses. A1c is a long-term blood sugar test. Your own change may differ. In a heart study of adults with type 2 diabetes and heart disease or risk factors, about 12 in 100 on Trulicity had death from heart or blood vessel disease, a heart attack or a stroke, versus about 13 in 100 on placebo over 5.4 years. It is not a weight-loss approval.
Limits (verbatim): The A1c range is from AWARD-11 and not a personal forecast. REWIND tested a three-part cardiovascular outcome in eligible adults, not all patients or a proven single heart mechanism.
Safety (verbatim): The boxed warning reports thyroid C-cell tumors in rats; whether this occurs in people is unknown. The label says Trulicity must not be used with a personal or family history of medullary thyroid cancer, MEN2, or a prior serious allergy to dulaglutide or its ingredients. Urgent symptoms and any treatment decision need a clinician.
Borrador en español — pendiente de revisión profesional
Trulicity actúa sobre los receptores GLP-1 del páncreas. Cuando el azúcar en la sangre está alta, esto ayuda al cuerpo a liberar insulina y a reducir una señal que eleva el azúcar. Es una inyección semanal, no insulina. En un estudio de 36 semanas, los valores promedio de A1c bajaron alrededor de 1,5 a 1,8 puntos en tres dosis estudiadas. La A1c es una prueba del azúcar en la sangre a largo plazo. El cambio de cada persona puede ser distinto. En un estudio cardiovascular de adultos con diabetes tipo 2 y enfermedad del corazón o factores de riesgo, alrededor de 12 de cada 100 personas que recibieron Trulicity tuvieron muerte cardiovascular, un infarto no mortal o un accidente cerebrovascular no mortal, frente a alrededor de 13 de cada 100 que recibieron placebo durante 5,4 años. Trulicity no está aprobado para bajar de peso.
Límites: El intervalo de A1c proviene de AWARD-11 y no predice el resultado de una persona. REWIND estudió un resultado cardiovascular combinado de tres partes en adultos que cumplían los criterios del ensayo; no evaluó a todas las personas ni demostró un único mecanismo de protección del corazón.
Seguridad — advertencia destacada: En ratas se observaron tumores de las células C de la tiroides; se desconoce si esto ocurre en personas. Según la ficha técnica, Trulicity está contraindicado si la persona o un familiar han tenido cáncer medular de tiroides, si la persona tiene neoplasia endocrina múltiple de tipo 2 (MEN2), o si ha tenido una reacción alérgica grave a la dulaglutida o a un ingrediente del producto. Los síntomas urgentes y cualquier decisión de tratamiento requieren atención de un profesional clínico.
Terminology and back-translation checks
| English concept | Spanish seed | Required back-translation check |
|---|---|---|
| GLP-1 receptors in pancreas | receptores GLP-1 del páncreas | Preserve receptor as the target, not insulin itself. |
| Weekly shot, not insulin | inyección semanal, no insulina | Do not convert this into a self-injection schedule or imply an insulin product. |
| A1c mean change, three doses, 36 weeks | valores promedio de A1c; 1,5 a 1,8 puntos; 36 semanas | Preserve percentage-point change, study duration and group-average scope. Decimal comma is locale-specific; no personal forecast. |
| CV death, nonfatal MI or nonfatal stroke composite | muerte cardiovascular, infarto no mortal o accidente cerebrovascular no mortal | Reviewer must choose locale-appropriate stroke wording and preserve that this is one three-part composite. |
| REWIND 12 vs 13 per 100, 5.4 years | 12 de cada 100 frente a 13 de cada 100; 5,4 años | Rounded natural-frequency text is not the exact 594/4,949 versus 663/4,952 trial arithmetic; preserve adult eligibility. |
| Rat C-cell tumors; human relevance unknown | tumores de células C en ratas; se desconoce en personas | Do not state proven human causation or dismiss the boxed warning. |
| Personal/family MTC, MEN2, prior serious product allergy | cáncer medular de tiroides propio o familiar; MEN2; reacción alérgica grave previa | Preserve all three formal contraindications and dulaglutide/excipient scope. |
Release and QA gates
- [VERIFY] A native Spanish-speaking health professional chooses the intended locale, reviews “derrame cerebral,” MTC/MEN2 terminology, emergency register and the complete current label safety context. The reviewer should confirm that the Spanish A1c number means percentage points, not percent relative change.
- [VERIFY] A separate reviewer back-translates without seeing the English source, then compares the three composite endpoints, rounded frequencies, trial duration, eligibility, boxed warning and contraindications to the saved English and current US label.
- [VERIFY] Review the pen's own Instructions for Use and the label's ≥72-hour missed-dose condition in any adjacent live content. This seed gives no individual dose, missed-dose or switching instruction.
- [FOUNDER TO SUPPLY] Named native-language health-professional reviewer, credentials, approval date and locale, plus clinical/accessibility review tied to the exact final page version. No page, recording or animation has been published from this seed.
Sources: Current Trulicity US label; REWIND primary abstract.